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ABSTRACT 
The aging of the population as result of elongated life expectancy will increase also the 
number of individuals affected by dementing disorders leading to loss of independence and 
ability to cope with the problems of everyday life. Alzheimer’s disease (AD) is the most 
common form of dementia, affecting up to 20 % of population aged over 90 years. Most AD 
cases take place in late life, but a minority is affected as early as the age of 30 years, these being 
termed early-onset AD cases. These rare cases are often attributable to autosomal dominant 
mutations in the amyloid precursor  protein (APP) and presenilin (PSEN) 1 and 2 genes that 
cause the earlier onset of symptoms like memory loss and confusion and neuropathological 
changes including neuronal loss, intracellular neurofibrillary tangles and extracellular amyloid 
deposits. Nonetheless, the mystery behind a substantial amount of AD cases, i.e. the late-onset 
cases, remains unsolved, since the only widely established susceptibility gene, the APOE, 
accounts for only approximately half of the late-onset AD cases. 
In the present series of studies, the objective was to identify new susceptibility loci for 
late-onset AD and to study their expressional changes in AD or in AD models using molecular 
biological approaches such as single nucleotide polymorphisms and reverse transcription 
polymerase chain reaction methods. Genetic loci recognized earlier as susceptibility loci for 
late-onset AD in whole genome scan at 1p36.12 and 15q21.1 encompassing HSPG2 and CYP19 
genes were studied. The expressional changes in the CYP19 gene encoding an enzyme involved 
in estrogen metabolism, a hormone with controversial effects on AD, was studied in a mouse 
model of estrogen deprivation and replacement therapy. Also, the expression of seladin-1, an 
enzyme protective in apoptosis, was studied in AD and Lewy body dementia cases, and in an 
AD mouse model. 
A cluster of CYP19 SNPs was found to form a risk haplotype that was independent of 
sex, age and APOE polymorphism. The HSPG2 A allele in conjunction with APOE ε4 allele 
doubled the risk of AD compared to the APOE ε4 allele alone, and the tau pathology was more 
prominent in HSPG2 A and APOE ε4 carriers than in APOE ε4 allele carriers alone, suggesting 
that HSPG2 and APOE might interact at the cellular level impacting more on tau pathology 
rather than influencing Aβ pathology. The down-regulation of seladin-1 expression was specific 
for AD, and it was associated with hyperphosphorylation of tau protein. These genes associated 
with AD in the present studies may represent potential targets for further genetic and functional 
analysis in the field of AD therapeutics.  
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1. INTRODUCTION 
The most common form of dementia among aging people is Alzheimer's disease (AD), 
which involves the parts of the brain controlling thought, memory and language. The 
disease usually begins after the age of 60 years, and the risk increases with age, 
affecting 0.6% of population for ages 65-69 years, but up to 22.2% of the population 
over 90 years of age (Lobo et al. 2000). Thus age is the most important known risk 
factor for AD.  
Despite decades of intensive research in the field of AD, the causes of the disease still 
remain a mystery. There are a multitude of pathological hallmarks and biological 
changes in AD, indicating that there probably is not one single cause, instead several 
genetic, environmental and lifestyle factors contribute to the disease development, 
affecting each person differently. To recognize the risk factors and genes for such a 
multifactorial, complex disease is extremely challenging and laborious compared to 
single gene disorders, where defects in a single gene result in a characteristic disease 
phenotype.  
The most important known risk factor for AD is age. Family history is another risk 
factor, with genetics playing a considerable role in familial early-onset AD cases, a rare 
form of AD (< 5%) that usually occurs between the ages of 30 and 60 years. The more 
common form of AD is known as late-onset AD and this occurs later in life, but here no 
obvious inheritance pattern is seen. One form of a cholesterol carrying protein apoE, the 
ε4 allele, lowers the age of onset in AD, being the only late-onset AD susceptibility 
gene currently recognized in different ethnic populations. One APOE ε4 allele decreases 
the age of onset by five years, and two alleles accelerate the age of onset by nine years 
in late-onset AD cases (Tsai et al. 1994). However, there probably are several other 
genetic variants which may interact with each other, either predisposing to the disease 
or protecting against it, but they remain to be discovered. 
The most reasonable approach to search for factors contributing to the disease 
development is to aim at elucidating the mechanisms underpinning the pathophysiology 
of the disease. The hallmark pathologic lesions of AD are the extracellular amyloid 
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plaques and intracellular neurofibrillary tangles (NFT). Amyloid plaques are mainly 
composed of β-amyloid (Aβ) peptides, and their production is most clearly increased 
when amyloid precursor protein (APP) or presenilin (PSEN) genes carry mutations that 
affect the processing of APP, usually leading to the early-onset forms of AD (Goate et 
al. 1991, Levy-Lahad et al. 1995, Sherrington et al. 1995). NFTs, on the other hand, 
consist of paired helical filaments, that are formed by the microtubule-associated protein 
tau (Kosik et al. 1986). The Braak staging based on the NFT pathology, describes the 
severity of AD according to the distribution of NFT pathology in different brain areas 
(Braak and Braak 1995). In addition, nerve cells are lost in brain areas vital to memory 
and other mental abilities, and the levels of the neurotransmitter acetylcholine are lower 
in the AD brain (Davies and Maloney 1976, Ball 1977, Davies 1979). Glucose 
metabolism is also impaired in AD brains (Adolfsson et al. 1980), but the main question 
remains: are these observed changes involved in the disease process predisposing to AD 
or are they merely a consequence of some still unknown factor that actually is behind 
the disease? 
In addition to genetics and APOE, the roles of education, diet and environment in the 
development of this disease has been investigated. Increasing evidence shows that some 
of the risk factors for heart disease and stroke, such as high blood pressure (Skoog et al. 
1996), high cholesterol (Kalmijn et al. 1997, Notkola et al. 1998, Kivipelto et al. 2001), 
and low levels of the vitamin folate (Joosten et al. 1997), may predispose individuals to 
AD. However, evidence is gathering for physical, mental, and social activities as 
protective factors against AD (Scarmeas et al. 2001, Seidler et al. 2003).  
The lifetime risk of a genetically influenced multifactorial disorder like AD, is 
estimated to be 60% in western populations (Baird et al. 1988). Common clinical 
disorders have significant genetic components, as defined by the attributable risk 
(Lander and Schork 1994), and the objective of the present series of studies was to 
search for genes that might affect the risk of suffering AD, and thus possibly elucidate 
the mechanisms behind the disease. The basis for the majority of the present studies is 
the previously conducted genome-wide linkage mapping, that identified multiple loci 
associated with AD (Hiltunen et al. 2001). Many moderate susceptibility effects have 
been found in the Northern Savo population used also in the present series of studies 
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(table 1). It is important to identify the unmapped susceptibility loci if one wishes to 
understand the mechanisms behind the pathophysiology of the disease and to estimate 
the disease risk, and thereafter to be able to explore and design effective drug therapies 
and means to prevent or delay the disease initiation and progression. 
Table 1. Candidate genes studied in Northern Savo population. 
Gene Chromosomal 
location  
Association 
with AD 
Studya 
AACT 14q32 Negative (Helisalmi et al. 1997) 
BCHE 3q26 Positive b (Hiltunen et al. 1998) 
APOE   -491A/T 19q13.32 Positive b (Helisalmi et al. 1999) 
PSEN1 E318G 14q24.3 Positive b (Helisalmi et al. 2000a) 
NPY 7p15 Negative (Helisalmi et al. 2000b) 
MPO  17q23 Positive b (Reynolds et al. 2000) 
A2M  12p13-12 Positive b (Pirskanen et al. 2001) 
IL1A 2q14 Negative (Pirskanen et al. 2002) 
HSPG2 1p36.12 Positive b (Iivonen et al. 2003) 
ICAM1 19p13 Negative (Mattila et al. 2003) 
NCSTN 1q22-23 Positive c (Helisalmi et al. 2004a) 
APOD  3q26 Positive c (Helisalmi et al. 2004b) 
NEP  3q25 Positive b,c (Helisalmi et al. 2004c) 
CYP19 15q21.1 Positive b,c (Iivonen et al. 2004) 
BDNF 11p13 Negative (Vepsäläinen et al. 2005) 
TRKB 9q22 Negative (Vepsäläinen et al. 2005) 
a Populations do not fully overlap.  
b Association to a single nucleotide polymorphism. 
c Association to a haplotype. 
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2. REVIEW OF THE LITERATURE 
2.1. Alzheimer’s disease 
AD is a progressive, neurodegenerative disease leading to dementia, and eventually to 
death. It is the most common form of dementia in the elderly with prevalence of 0.6% 
for individuals aged  65 to 69 years, and 22.2% for those aged over 90 years (Lobo et al. 
2000). AD and its brain pathology were first described in 1907 by the German physician 
Alois Alzheimer in a 51-year-old woman. AD is characterized by memory loss and 
confusion, related to a distinctive combination of neuropathological changes including 
neuronal loss, intracellular neurofibrillary tangles (NFT) and extracellular amyloid 
plaques. Amyloid plaques and NFTs are also found in normally aged brains, although in 
reduced numbers, and therefore, they are considered as age-related changes. 
AD is subdivided into early (< 65 years) and late onset (>65 years) forms. About 10% 
of AD cases are familial with an autosomal dominant inheritance and these cases have 
often early onset. In these families, single point mutations in amyloid precursor protein 
(APP), or presenilins 1 and 2 (PSEN 1/2) result in cleavage of APP to neurotoxic β-
amyloid peptides (Aβ) which is deposited in the core of neuritic plaques (Goate et al. 
1991, Levy-Lahad et al. 1995, Sherrington et al. 1995). In addition to these cases, 30% 
of AD cases have a positive family history of AD, but insufficient evidence of 
autosomal dominant inheritance (van Duijn et al. 1991). Therefore, up to 60% of AD 
cases, termed as sporadic, do not have a family history of AD. The early onset cases 
appear similar to sporadic cases with the exception of more severe symptoms and 
pathology, and an earlier age of onset.  Exploring the genetic background behind the 
sporadic late onset cases, has revealed apolipoprotein E (ApoE)  to be a risk factor of 
AD (Corder et al. 1993, Saunders et al. 1993). Since then, almost 100 genes have been 
tested for association with AD throughout the world (table 2), but none of them has 
consistently conferred susceptibility to AD (Bertram and Tanzi 2004). Nevertheless, a 
number of studies have identified several additional AD susceptibility loci in addition to 
APOE, in both linkage and association studies, pointing to the existence of novel AD 
genes on several chromosomes. 
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Table 2. A sample of AD candidate genes studied worldwide.  
Gene Chromosomal 
location  
Relevance to AD pathogenesis Study 
Early-onset    
PSEN2 1q31-42 Essential for γ-secretase activity (?) (Levy-Lahad et al. 1995) 
PSEN1 14q24.3 Componen of γ-secretase complex (Sherrington et al. 1995) 
APP 21q21.3 Precursor of Aβ (Goate et al. 1991) 
Late-onset    
HSPG2 1p36 Component of  Aβ plaques? (Rosenmann et al. 2004) 
MTHFR 1p36 Homocysteine metabolism (Chapman et al. 1998) 
NCSTN 1q22-23 Component of γ-complex (Dermaut et al. 2002) 
IL1A 
IL1B 
IL1RN 
2q14 Inflammatory response (Grimaldi et al. 2000) 
TF 3q22 Iron transporter, oxidative stress (Namekata et al. 1997) 
NEP 3q25 Degradation of Aβ (Oda et al. 2002) 
APOD 3q26 Lipid metabolism (Desai et al. 2003) 
SNCA 4q21 Component of Aβ plaques (Xia et al. 1996) 
TNFA 6p21 Inflammation (Tarkowski et al. 2000) 
HLA-A2 6p21 Inflammation (Small et al. 1991) 
ESR1 6q25 Mediator of estrogen effects (Brandi et al. 1999) 
IL6 7p21 Nerve cell differentation (Papassotiropoulos et al. 
1999) 
NOS3 7q36 Synthesis of nitric oxide, apoptosis (Dahiyat et al. 1999) 
LPL 8p22 Plasma lipid transportation (Baum et al. 1999) 
VLDL-R 9p24 Cholesterol metabolism (Chen et al. 1998) 
UBQLN1 9q22 PSEN biosynthesis and degradation (Bertram et al. 2005) 
PLAU 10q22 Plasminogen activator, degradation of Aβ (Finckh et al. 2003) 
CTNNA3 10q22 Binds β-catenin, Wnt signalling (Ertekin-Taner et al. 2003) 
IDE 10q23 Degradation of Aβ (Abraham et al. 2001) 
CTSD 11p15 Lysosomal aspartyl protease, 
cleavage of APP? 
(Papassotiropoulos et al. 
2000) 
FE65 11p15 APP binding protein (Cousin et al. 2003b) 
BCHE 11p15 Component of Aβ plaques (Lehmann et al. 1997) 
BDNF 11p13 Survival of neruronal cells (Nishimura et al. 2005) 
A2M 12p13 Degradation of Aβ (Blacker et al. 1998) 
LRP 12q13 Receptor for APOE and A2M (Lendon et al. 1997) 
NOS1 12q24 Neurotransmitter properties in brain (Liou et al. 2002) 
DLST 14q24 Enenrgy metabolism (Cruts et al. 1995) 
AACT 14q32 Component of Aβ plaques (Kamboh et al. 1995) 
5HTT 17q11 Serotonin transport (Li et al. 1997) 
BLMH 17q11 Cysteine protease, BACE activity? (Montoya et al. 1998) 
MAPT 17q21 Forms PHF of NFTs (Crawford et al. 1999) 
ACE 17q23 Hypertension (Chapman et al. 1998) 
MPO 17q23 Phagocytosis, inflammation (Reynolds et al. 1999) 
ICAM1 19p13 Inflammation (Pola et al. 2003) 
APOE 19q13.32 Aβ aggregation (Saunders et al. 1993) 
PRNP 20p13 Oxidative stress? (Casadei et al. 2001) 
CST3 20p11 Protease inhibitor, Aβ fibril formation (Parfitt et al. 1993) 
CYP2D6 22q13 Drug metabolism (Saitoh et al. 1995) 
MAOA Xq21-26 Metabolism of monoamine 
neurotransmitters 
(Takehashi et al. 2002) 
 
The grossest hallmark lesion of AD brain is atrophy in the cerebral hemispheres, medial 
temporal lobes, hippocampus and amygdala, although this is not always apparent in AD. 
22 
 
Severe, generalized atrophy is more common in a minority of early onset AD cases than 
in cases developing AD later in life. In family members with AD mutations, cerebral 
atrophy can be detected even before the onset of psychological or clinical deterioration 
(Fox et al. 1996). The microscopic pathology of AD brain consists of argyrophilic 
plaques and NFTs, along with neuron loss, activated microglia, neuropil threads, 
granuovascular degeneration, Hirano bodies and amyloid angiopathy. NFTs are 
abnormal intracellular structures composed mainly of bundles of hyperphosphorylated 
tau proteins forming paired helical filaments (PHF). Argyrophilic plaques are 
extracellular deposits mainly composed of Aβ, and they are divided into diffuse and 
neuritic plaques. Neuritic plaques have a heterogenous appearance with dense central 
core consisting of amyloid fibrils. Around the core, microglial cells, glial and neuritic 
processes, amyloid P component, complement components, apolipoproteins E and J, 
acetylcholinesterase, α1-antichymotrypsin, proteoglycans, growth factors and their 
receptors, can be found (Esiri 2001). Diffuse plaques, on the other hand, are mainly 
composed of Aβ, and it has been proposed that the diffuse plaques represent the early 
form of neuritic plaques in the disease development. 
The clinical diagnostic criteria most widely used for AD are those of the National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
disease and Related Disorders Association (NINCDS/ADRDA) (McKhann et al. 1984). 
The criteria are divided into possible, probable and definite, the last one requiring a 
histological diagnosis together with the clinical picture. This is one characteristic feature 
of AD; postmortem neuropathology provides the only method to definitely diagnose AD 
on a person that has clinically been diagnosed as probable AD during his/her lifetime. 
The histopathological diagnosis is generally based on the criteria defined by the 
Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) (Mirra et al. 1991).  
In the past few years, brain imaging techniques have also been used in AD diagnostics. 
Functional imaging techniques reveal the changes in metabolism, while structural 
imaging allows the detection of atrophy and ischemic changes, offering better 
sensitivity and specificity of diagnosis than functional imaging, but still they provide 
only an aid to diagnosis (Fox et al. 2001). Tau-protein and Aβ1-42, the main 
23 
 
constituents of NFTs and amyloid plaques, are the most promising candidates as 
biological markers of AD. Along with brain imaging techniques, the biochemical testing 
of tau-protein and Aβ1-42 in cerebrospinal fluid (CSF) has been used in AD 
diagnostics. CSF-tau levels are significantly increased in patients with AD compared to 
subjects with other neurological diseases and controls (Arai et al. 1995), while Aβ1-42 
in CSF is decreased (Motter et al. 1995). The CSF-tau measurement can be used alone 
or in combination with Aβ1-42 measurement to detect AD in its early stages, and to rule 
out some dementing disorders resembling AD (Arai et al. 2001). 
2.2. Amyloid precursor protein 
2.2.1. Amyloid precursor protein metabolism 
The main component of the AD-associated amyloid plaques is the 39-43 amino acid 
amyloidogenic peptide Aβ, which is derived by the proteolytic processing of amyloid 
precursor protein (APP) (figure 1). APP is a type 1 membrane protein encoded in 
chromosome 21 by 18 exons, three of which are alternatively spliced resulting in a 
variety of isoforms. The isoform of 695 amino acids is the primary APP present in 
neuronal tissue, while isoforms APP751 and APP770 are widely expressed in non-
neuronal cells (Neill et al. 1994). The three alternatively spliced exons encode a domain 
of unknown function that has homology to Kunitz protease inhibitor domain, and a 
domain which when included in APP transcript, disrupts a consensus sequence site used 
for heparin sulphate modification of the protein (Tanaka et al. 1988, Clarris et al. 1997, 
Wasco 2001).  
APP functions as a cell surface receptor potentially performing physiological functions 
relevant to neurite growth, neuronal adhesion, cell survival, neuroprotection, 
synaptogenesis, synaptic plasticity and axonogenesis (Mattson 1997). In addition, it can 
inhibit Notch signalling and regulate transcription by forming a transcriptionally active 
complex with the adaptor protein Fe65 and the histone acetyltransferase Tip60 (Cao and 
Sudhof 2001). After cleavage near the membrane, APP is in the form of a secreted 
protein (sAPP) that has the same functions as the full-length APP. APP is a member of 
an evolutionarily conserved gene family, and two mammalian amyloid precursor-like 
proteins, ALPL1 and ALPL2 have been identified (Sprecher et al. 1993, Wasco et al. 
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1993, Slunt et al. 1994). The overall structures as well as structural and functional 
domains are extremely well conserved in these proteins, with the exception of the Aβ 
domain, which is found only in APP.  
APP is processed by several enzymes. It is predominantly cleaved by α-secretase, 
resulting in the secretion of the N-terminal portion of APP (sAPPα) and inhibition of Aβ 
formation. The membrane bound C-terminal fragment of 83 amino acids (C83) is 
internalized and degraded, leading to the formation of a 3 kDa fragment (p3) during the 
process (Esch et al. 1990). Two members of ADAMs family (a disintegrin and 
metalloprotease family) of proteases, tumour necrosis factor alpha converting enzyme 
(ADAM17 or TACE) (Buxbaum et al. 1998) and ADAM10 (Lammich et al. 1999) have 
α-secretase activity. In addition, a minor portion of APP is cleaved by β-secretase, 
resulting in the formation of the N-terminal secreted APPβ (sAPPβ) and a C-terminal 
peptide of 99 amino acids (C99). The C99 contains the neurotoxic Aβ fragment, and 
subsequent to α- and β-secretase cleavage, C83 and C99 can be cleaved by γ-secretase 
to form p3 or Aβ. The most abundant forms of Aβ consist of 40 or 42 amino acids, of 
which the Aβ42 is more amyloidogenic peptide associated with AD. In addition to 
cleavage at amino acids 40 and 42, a new γ-secretase cleavage site at amino acid 49 was 
identified and termed as the ε-cleavage site (Sastre et al. 2001).  
β-secretase is an aspartyl protease known as BACE or Asp2 (Vassar et al. 1999), 
whereas γ-secretase is a complex of a minimum four proteins (Kimberly et al. 2003b). 
Transgenic mice over-expressing human APP, but lacking BACE1 gene, can be rescued 
from Aβ-dependent hippocampal memory deficits, and cholinergic dysfunction (Ohno 
et al. 2004). Moreover, BACE overexpression is not sufficient to produce beta-amyloid 
plaques, but simultaneous expression of BACE1 and its substrate (SweAPP) leads to 
accelerated amyloid plaque formation (Mohajeri et al. 2004). BACE activity increases 
with aging in human brains, suggesting that an age-related increase of BACE activity 
contributes to the increased production and accumulation of brain Aβ, potentially 
predisposing to Alzheimer's disease in humans (Fukumoto et al. 2004). In sporadic AD 
patients, this may actually happen since in these individuals the increased BACE 
activity is associated with an elevated Aβ load (Li et al. 2004). On contrary, sAPPα has 
neuroprotective effects since it reduces the neurotoxicity of glutamate and Aβ (Mattson 
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et al. 1993, Goodman and Mattson 1994), and sAPPα is ~ 100-fold more potent than 
sAPPβ in this function (Furukawa et al. 1996). This may be due to heparin binding 
domain VHHQK that is present in sAPPα, but not in sAPPβ. The secreted forms of APP 
have also memory enhancing properties (Meziane et al. 1998).  
The γ-secretase cleavage of APP is similar to γ-secretase cleavage of Notch, whose 
intracellular domain (NICD) activates transcription factors by interacting with nuclear 
transcription factors (Selkoe and Kopan 2003). γ- and ε-cleavage of APP produces an 
intracellular fragment named the APP intracellular domain (AICD or CTF-γ) that is a 
potent transactivator of transcription when coupled to a transmembrane region. 
Membrane-tethered AICD recruits Fe65 that is then released for nuclear translocation 
by γ-cleavage together with the AICD. Thus the transcriptional transactivation by APP 
and Notch may involve distinct mechanisms; whereas NICD directly functions in the 
nucleus, the AICD acts indirectly by activating Fe65 (Cao and Sudhof 2004). 
   
 
 
 
 
 
 
 
 
 
 
Figure 1. FAD-linked APP mutations and metabolism of APP via α- and β-secretase pathways. Black  
segment represents Aβ. 
The progressive deposition of Aβ is considered to be fundamental to the development of 
neurodegenerative pathology of AD, and moreover, the aggregation state of the Aβ 
peptide is probably a key factor in determining the toxicity of Aβ. Fibrillized Aβ is 
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known to be neurotoxic, whereas soluble Aβ peptides exhibit only little toxicity 
(Simmons et al. 1994, Howlett et al. 1995). Soluble Aβ monomers are used during the 
formation of protofibrils, an intermediate in the formation of fibrillar β-amyloid and this 
is also the rate limiting step in the formation process of amyloid fibrils. The protofibrils 
provide the nidus that accelerates conversion to fibrils and thence to plaques. The 
fibrillization may be regulated by many factors such as, acetylcholinesterase (AChE) 
(Inestrosa et al. 1996), metal ions Fe2+, Cu2+ and Zn2+ (Atwood et al. 1998), apoE, 
proteoglycans and glucose. Aβ deposition in AD may be a delicate balance involving 
enhanced production of Aβ, decreased clearance and the absence or presence of factors 
regulating the fibrillization process. Inhibitors of Aβ fibrillization that bind to the 
hydrophobic core region of the peptide, a fundamental component of its ability to 
aggregate, might provide one mean to halt or at least slow down the progression of AD 
(Howlett et al. 2001).  
2.2.2. Amyloid precursor protein mutations 
Mutations in APP gene, that are behind early-onset familial AD (FAD), are located 
around α-, β- and γ-secretase cleavage sites. To date, 14 pathogenic AD mutations in 
nine different loci have been identified (Alzheimer Disease & Frontotemporal Dementia 
Mutation Database; http://www.molgen.ua.ac.be/ADMutations/default.cfm). Mutation 
V717I known as London mutation is the most frequent APP mutation found in 23 AD 
families, while other mutations have been found only in one to three families. 
Presumably, the position of mutations influences the metabolism of the APP. Possibly, 
the AD mutations affect the cleavage of one of the three enzymes and consequently, the 
Aβ40 and Aβ42 levels in the brain. APP mutations in amino acid positions 714 to 717 at 
the γ-secretase site increase the ratio of Aβ42: Aβ40 (De Jonghe et al. 2001), and the 
Swedish double mutation K670N/M671L at β-secretase cleavage site increases both 
Aβ40 and Aβ42 deposits (Citron et al. 1992). β-secretase has a 100-fold activity with an 
APP substrate containing Swedish double mutation compared to wildtype APP (Vassar 
et al. 1999), and in this case, more C99 is available for γ-secretase to produce both Aβ 
peptides. Mutations in α-secretase site are linked to cerebral hemorrhages with 
amyloidosis of Dutch and Flemish type, where the Aβ peptide deposits, consisting 
mainly of Aβ40, are found in non-neuronal cells of the cerebral blood vessel walls 
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(Levy et al. 1990, Hendriks et al. 1992). Aβ with the Arctic mutation (E693G) forms 
protofibrils at a much higher rate and in larger quantities than wild-type Aβ, which may 
reflect a pathogenic mechanism for AD involving rapid Aβ protofibril formation leading 
to accelerated buildup of insoluble Aβ both intra- and/or extracellularly (Nilsberth et al. 
2001). 
2.3. γ-secretase components and pathway 
γ-Secretase is an intramembrane-cleaving aspartyl protease that catalyzes the 
proteolysis of APP, Notch and other type I transmembrane receptors, indicating that it 
normally serves as a mediator of diverse signaling pathways (Kimberly et al. 2003a). γ-
Secretase is a membrane protein complex comprising of PSEN, nicastrin (NCSTN), 
anterior pharynx-defective-1 (APH-1) and presenilin enhancer-2 (PEN-2) (figure 2), and 
it functions as a key step in the pathogenesis of AD, cleaving APP into Aβ. This 
unusual protease has a PSEN heterodimer in its catalytic site and a highly glycosylated 
NCSTN associated with it. γ-secretase components assemble into the proteolytically 
active γ-secretase complex in the Golgi/trans-Golgi network compartment (Baulac et al. 
2003), and they are expressed in a coordinated manner (Steiner et al. 2002); the over-
expression of PSEN and NCSTN is not sufficient for increased γ-secretase activity 
(Yang et al. 2002), but requires both APH-1 and PEN-2 to circumvent the tight 
regulation of γ-secretase activity in mammalian cells (Francis et al. 2002, Kimberly et 
al. 2002). The impact of co-expression of γ-secretase components on APP cleavage and 
Aβ production has not been shown in mammalian cells, because the co-expression of γ-
secretase components affects the endogenous APP expression levels of APP transfected 
cells thus preventing the accurate quantification of endogenous Aβ (Kimberly et al. 
2003b). However, co-expression of Drosophila APH-1, PEN-2, and NCSTN increases 
levels of PSEN fragments and γ-secretase cleavage of APP (Takasugi et al. 2003), and 
similar results have been obtained using mammalian γ-secretase components in yeast 
(Edbauer et al. 2003).  
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Figure 2. Hypothetical γ-secretase assembly pathway according to Hu and Fortini. NCSTN and APH-1 
associate in an early subcomplex, leading to stabilization of APH-1. The subcomplex regulates 
stabilization of PSEN holoprotein and its incorporation into a complex with NCSTN and possibly PEN-2. 
PEN-2 is required for endoproteolysis of PSEN holoprotein, although the point at which PEN-2 enters the 
pathway is unknown. 
There may be at least three distinct PSEN complexes; a ~150 kDa NCSTN-APH-1 
complex, a ~440 kDa γ-secretase complex, which contains additional components 
(PSEN-1 and PEN-2), and a high mass (≥670 kDa), low abundance heteromeric 
complex associated with high γ-secretase activity.  The ~440 kDa complex is a non-
functional intermediary complex stably and relatively abundantly present. The 
prevalence, although in low amounts, of the high molecular weight ≥670 kDa complex 
under conditions associated with functional γ-secretase activity, suggests that this 
complex is the species that contains full enzymatic activity. The lower mass (~150 kDa 
and ~440 kDa) complexes might then represent initial and intermediary complexes, 
while the high mass complex (≥670 kDa) could represent a functional complex that 
contains either additional components or the four known components in a higher order 
stoichiometry (e.g. 2:2:2:2) (Gu et al. 2004). 
2.3.1. Presenilin-1/2 
A member of the γ-secretase complex, PSEN-1 encoded by 12 exons in chromosome 
14q24, is a 52 kDa transmembrane protein with eight transmembrane domains. PSEN-2 
in chromosome 1q31 has 67% amino acid identity with PSEN-1 resulting in a 90 kDa 
transmembrane protein encoded by 10 exons. PSEN proteins are aspartyl proteases (Xia 
et al. 2000) that form the catalytic subunit of γ-secretase complex responsible for Notch 
and APP cleavage (Kimberly et al. 2003a). The full-length PSEN proteins are rapidly 
cleaved in the cytoplasmic loop into C- and N- terminal fragments (CTF and NTF), with 
only a small portion found as full-length PSEN proteins, suggesting that the 
heterodimers formed by CTF and NTF are the active form of the protein (figure 3). The 
endoproteolysis is tightly regulated, and consequently over-expression of PSEN leads to 
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the appearance of full-length PSEN, but does not increase in the levels of the fragments 
(Thinakaran et al. 1996). In addition to interacting with γ-secretase complex proteins, 
PSENs interact with signaling proteins, β- and ∆-catenins, and with glycogen synthase 
kinase-3β (GSK-3β) responsible for tau phosphorylation (Zhou et al. 1997, Takashima 
et al. 1998, Zhang et al. 1998). 
 
 
 
 
Figure 3. Structure of PSEN proteins and the endoproteolytic site. Functionally essential aspartate 
residues are shown by dots.  
The PSEN genes were linked to AD in 1995, when various missense mutations were 
localized in several families (Levy-Lahad et al. 1995, Rogaev et al. 1995, Sherrington et 
al. 1995). Defects in PSEN-1 cause the most severe form of AD, familial AD with 
complete penetrance and early onset age occurring as early as 24 years of age 
(Moehlmann et al. 2002), and to date altogether 142 pathogenic mutations have been 
found in the PSEN-1 gene  (http://www.molgen.ua.ac.be/ADMutations/default.cfm) 
(Coleman et al. 2004). PSEN-1 mutations are mainly missense mutations, leading to an 
amino acid change, and many of the mutations occur in single kindreds only. A few 
mutations include insertions or deletions leading to codon insertions/deletions or frame-
shift with premature stop codons or deletions of whole exons from the transcript. The 
mutations in PSEN-1 are located primarily within the transmembrane domains and in 
the N-terminal portion of the cytoplasmic loop, close to the endoproteolytic cleavage 
site. All PSEN-1 mutations analyzed to date affect the metabolism of the APP, 
increasing the levels of  Aβ42 deposited in senile plaques (Selkoe 1999). Altogether ten 
pathogenic mutations have been found in the PSEN-2 gene, with somewhat later onset 
ages, wide range of onset age and greater variability in penetrance than with PSEN-1 
mutations. All PSEN-2 mutations are missense mutations leading to an amino acid 
change (http://www.molgen.ua.ac.be/ADMutations/ default.cfm). 
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The biological function of PSEN mutations was known even before the genes were 
cloned; PSEN mutations increase Aβ1-42 production (Scheuner et al. 1996). In addition 
to this toxic gain of misfunction, mutations may result in loss of function of γ-secretase 
activity (Wolfe et al. 1999) and Notch signaling (Berezovska et al. 2000, Moehlmann et 
al. 2002), when they occur in either of two transmembrane aspartate residues (Asp257 
or Asp385). Mutations in aspartate residues prevent the endoproteolysis of PSEN-1, and 
subsequently the formation of active PSEN-1.  
Presenilins interact also with glycogen synthase kinase-3β (GSK-3β) responsible for tau 
phosphorylation (Takashima et al. 1998). PSEN-1 mutations inhibit 
phosphatidylinositol 3-kinase (PI3K) and its downstream effector Akt activation, thus 
promoting GSK-3β activity and tau over-phosphorylation. PSEN-1 may thus prevent 
development of AD pathology by activating the PI3K/Akt signaling pathway, but in 
contrast, PSEN-1 mutations may promote AD pathology by inhibiting this pathway 
(Baki et al. 2004).  
Mutations in PSEN-1 gene leading to deletion of exon nine (∆E9) prevent the 
endoproteolysis of PSEN-1 protein. The primary effect of this mutation may be the 
deletion of exon nine, which in its immature form inhibits the activation of γ-secretase 
and occupies the substrate-binding site. However, when the exon is deleted, the 
inhibition of γ-secretase activation is also abolished (Knappenberger et al. 2004), 
leading to extremely high rates of Aβ1-42 production (Houlden et al. 2000). In contrast, 
deletion of the PSEN-1 gene produces developmental abnormalities indicating a loss in 
Notch signaling (Wong et al. 1997), and decreased γ-secretase processing of APP, 
resulting in dramatic declines in Aβ levels (De Strooper et al. 1998).  
2.3.2. Nicastrin 
Nicastrin (NCSTN) is a type I transmembrane glycoprotein that forms high molecular 
weight complexes with presenilins (Yu et al. 2000). NCSTN encoded in chromosome 
1q22 is a component of the γ-secretase complex probably representing a stabilizing 
cofactor required for the assembly of the γ-secretase complex. The Caenorhabditis 
elegans orthologue of NCSTN, APH-2, is essential for Notch signalling during early 
embryogenesis (Goutte et al. 2002); however, the exact role of APH-2/NCSTN is not 
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known. Recent studies revealed that NCSTN and APH-1 initially form a subcomplex to 
bind and stabilize PSEN, and then PEN-2 confers the γ-secretase activity and facilitates 
endoproteolysis of PSEN (LaVoie et al. 2003, Shirotani et al. 2004). A region at the C-
terminal end of NCSTN, encompassing the last 50 residues of the transmembrane 
domain, and the cytoplasmic domain are important for mediating interactions between 
human PSEN-1, APH-1, and PEN-2 (Morais et al. 2003).  
NCSTN in γ-secretase complex is highly glycosylated, and mutations inhibiting the 
glycosylation and stability of NCSTN halt the binding with PSENs (Tomita et al. 2002). 
NCSTN appears to be critical for the trafficking of PSENs and APP to the cell surface 
(Kaether et al. 2002, Li et al. 2003), and suppression of NCSTN expression results in 
phenotypes similar to PSEN or Notch1 suppression (Li et al. 2003). NCSTN binds C-
terminal derivatives of APP, C83 and C99, and modulates the production of the Aβ of 
these derivatives. Missense mutations in conserved hydrophilic domain of NCSTN 
increase Aβ1-42 and Aβ1-40 secretion, whereas deletions in this domain inhibit Aβ 
production (Yu et al. 2000). However the reports of genetic studies associating NCSTN 
to early onset AD are conflicting (Dermaut et al. 2002, Confaloni et al. 2003, Cousin et 
al. 2003a, Orlacchio et al. 2004), though an association with a subpopulation of late 
onset AD has been found (Helisalmi et al. 2004a). 
2.3.3. APH-1 
Anterior pharynx-defective-1 (APH-1) is a highly conserved membrane protein with 
seven transmembrane domains and it topologically resembles the seven-transmembrane 
domain receptors. Similar to the loss of PSEN or NCSTN, inactivation of endogenous 
APH-1 decreases presenilin levels, accumulates γ-secretase substrates (APP C-terminal 
fragments), and reduces γ -secretase products (Aβ and intracellular domains of APP and 
Notch). These data indicate that APH-1 probably is a functional component of the γ-
secretase complex required for intramembrane proteolysis of APP and Notch (Francis et 
al. 2002), involved in early stages of γ-secretase complex assembly, and required for 
proper cell-surface localization of NCSTN (Goutte et al. 2002). In addition, APH-1 is 
involved in the stabilization and glycosylation of NCSTN, and in scaffolding NCSTN to 
the immature γ-secretase complex which stabilizes PSEN holoprotein (LaVoie et al. 
2003).  
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APH-1 is processed by several endoproteolytic events, and one of these cleavages is 
strongly up-regulated by co-expression of NCSTN generating a stable C-terminal 
fragment of APH-1 that associates with NCSTN (Fortna et al. 2004). The association 
between NCSTN and APH-1 may occur shortly after APH-1 synthesis, and the 
interaction between these two proteins is mediated by transmembrane domains of APH-
1. In C. elegans, a mutation of the conserved transmembrane Gly123 in aph-1 leads to a 
Notch/glp-1 loss-of-function phenotype. The corresponding mutation in mammalian 
APH-1a (G122D) disrupts the physical interaction of APH-1a with immature NCSTN 
and PSEN holoprotein as well as with mature NCSTN, PSEN and PEN-2, and reduces 
γ-secretase activity in intramembrane proteolysis of Notch. Conserved transmembrane 
residues Gly122, Gly126, and Gly130 in the fourth transmembrane region of 
mammalian APH-1a are part of the membrane helix-helix interaction GXXXG motif 
and are essential for the stable association of APH-1a with PSEN, NCSTN, and PEN-2. 
These findings suggest that APH-1 plays a GXXXG-dependent scaffolding role in both 
the initial assembly and in the subsequent maturation and maintenance of active γ-
secretase complex (Lee et al. 2004).  
Over-expression of APH-1 facilitates PEN-2-mediated PSEN-1 proteolysis, resulting in 
a significant increase in PSEN-1 fragments (Luo et al. 2003), whereas down-regulation 
of APH-1 alleviates the accumulation of full-length PSEN-1. This suggests that APH-1 
is an essential cofactor for stabilizing nascent full-length PSEN-1, but in the absence of 
APH-1, PSEN-1 holoprotein is diverted to rapid protein degradation pathway 
(Ratovitski et al. 1997) rather than to the endoprocessing pathway, which generates 
PSEN-1 NTF and CTF. Nevertheless, it is still possible that APH-1 may be involved in 
stabilizing PSEN-1 fragments. PSEN-1 over-expression destabilizes APH-1 expression, 
whereas NCSTN stabilizes APH-1 expression. Because PSEN prevents the over-
accumulation of APH-1 by NCSTN, it is possible that stabilization of PSEN holoprotein 
by APH-1 leads ultimately to the removal and degradation of APH-1 from the maturing 
complex (Hu and Fortini 2003) (figure 2). 
Mutations in aph-1 cause defects in Notch signalling at embryogenesis seen as a marked 
defect in the ability to localize the Notch pathway component aph-2/ncstn, similar to 
mislocalization of aph-2/ncstn seen in inactivation of PSEN or NCSTN (Goutte et al. 
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2002, Hu and Fortini 2003), indicating that APH-1 is required for Notch signalling 
throughout development. In a genetic study with an Italian AD population, no 
association was found between APH-1 and sporadic AD (Poli et al. 2003). 
2.3.4. PEN-2 
Presenilin enhancer-2 (PEN-2) is a transmembrane protein that was found through 
strong interactions with sel-12 and aph-2, C. elegans orthologies to human PSEN and 
NCSTN (Francis et al. 2002). Human PEN-2 is a 101-amino acid protein containing two 
putative transmembrane domains (Crystal et al. 2003). PEN-2 is a component of the γ-
secretase complex, and it probably represents the last maturation step of the γ-secretase 
complex, facilitating endoproteolysis of presenilin and conferring γ-secretase activity 
(figure 2).  
The human PEN-2 and APH-1 proteins interact closely with each other and with PSEN. 
The N-terminal domain of PEN-2 is important for interactions with PSEN-1 (Crystal et 
al. 2003). APH-1, PEN-2, and NCSTN are required for the activity and accumulation of 
γ-secretase; inactivation of APH-1, PEN-2, or NCSTN reduces γ-secretase cleavage of 
APP and Notch substrates and levels of processed PSEN (Francis et al. 2002). Down-
regulation of PEN-2 expression abolishes the endoproteolysis of PSEN-1, whereas over-
expression of PEN-2 promotes the production of PSEN-1 fragments, indicating a critical 
role for PEN-2 in PSEN-1 endoproteolysis (Luo et al. 2003). PEN-2 is also required for 
the stabilization of the PSEN fragment heterodimer within the γ-secretase complex 
following PSEN endoproteolysis, and this function critically depends on the PEN-2 C-
terminus. Thus, PEN-2 is generally required for γ-secretase complex maturation 
independent of its activity in PSEN-1 endoproteolysis (Prokop et al. 2004). 
PSEN-1 regulates the subcellular localization of PEN-2: in the absence of PSEN, PEN-2 
is sequestered in the endoplasmic reticulum (ER) and not transported to post-ER 
compartments, where the mature γ-secretase complexes reside. PSEN deficiency also 
leads to destabilization of PEN-2, which is alleviated by proteasome inhibitors. PEN-2 
is ubiquitylated prior to degradation and presumably retrotranslocated from the ER to 
the cytoplasm. In other words, failure to become incorporated into the γ-secretase 
complex leads to degradation of PEN-2 through the ER-associated degradation-
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proteasome pathway (Bergman et al. 2004). PSEN regulates PEN-2 levels 
posttranslationally by preventing PEN-2 degradation by the proteasome. Thus, the 
amount of PEN-2 protein is effectively titrated by its PSEN binding partner, and the 
rapidity with which PEN-2 is degraded in the absence of PSEN interactions, could 
provide a mechanism to tightly regulate γ-secretase complex assembly (Crystal et al. 
2004).  
2.3.5. Notch and other γ-secretase substrates 
The Notch receptor is a membrane-bound transcription factor that is released to the 
nucleus by a two-step cleavage mechanism in response to ligand binding. Notch is 
involved in cell fate decisions during both development and adulthood, and the core 
Notch signalling pathway involves complex proteolytic processing. The full-length 
Notch protein synthesized as a 300 kDa precursor protein is a short-lived species, which 
is mainly cleaved at cleavage site 1 (S1) by furin-like convertase (Blaumueller et al. 
1997, Logeat et al. 1998). These two parts reassemble into a heterodimer that forms the 
Notch receptor found in the plasma membrane. DSL (Delta and Serrate/Jagged in 
Drosophila and vertebrates, Lag-2 in C. elegans) ligands interact with the extracellular 
domain rendering region proximal to the membrane susceptible to cleavage by 
metalloproteases of the ADAM family, which include ADAM17/TACE (TNF-alpha 
converting enzyme) in vertebrates (Brou et al. 2000). The cleavage site is referred to as 
S2, and the resulting C-terminal fragment is called NEXT (Notch extracellular 
truncation). NEXT undergoes further cleavage at a third site (S3) located within its 
transmembrane domain by γ-secretase resulting in proteolytic release of the Notch 
intracellular domain (NICD), which translocates into the nucleus and interacts with 
DNA-binding proteins affecting transcriptional regulation by switching on a DNA-
bound co-repressor CSL (CBF1/RBPjk in vertebrates, suppressor of hairless in 
Drosophila, Lag-1 in C-elegans) into an activating complex (Greenwald 1998, 
Artavanis-Tsakonas et al. 1999, Kopan and Goate 2002).  
Recently, it was found that Notch ligands Delta1 and Jagged2 are also subject to PSEN-
dependent, intramembranous γ-secretase processing, resulting in the production of 
soluble intracellular derivatives. The ectodomain of mammalian Jagged is cleaved by an 
ADAM17-like activity. Notch stimulates the ectodomain shedding of the ligand and 
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yields membrane-tethered C-terminal fragments (CTFs) of Jagged and Delta that 
accumulate in cells expressing the mutant form of PSEN, indicating that a similar 
molecular apparatus is responsible for intramembranous processing of Notch and its 
ligands (Ikeuchi and Sisodia 2003). PSEN forms stable complexes with Delta and 
Jagged and with their respective CTFs. PSEN/ γ-secretase then mediates the cleavage of 
CTFs to release the Delta and Jagged intracellular domains, portions which can enter the 
nucleus. The ligand CTFs compete with an activated form of Notch for cleavage by γ-
secretase and are thus able to inhibit Notch signaling in vitro (LaVoie and Selkoe 2003). 
The cytoplasmic derivative of Delta1 was shown to stimulate nuclear transcription, and 
the soluble Jagged intracellular domain activated gene expression via the transcription 
factor AP1, suggesting that Delta1 and Jagged2 play dual roles as activators of Notch 
receptor signaling and as receptors that mediate nuclear signaling events via γ-secretase-
generated cytoplasmic domains (Ikeuchi and Sisodia 2003). Notch and its cognate 
ligands are also processed by the same molecular machinery and may antagonistically 
regulate each other's signaling (LaVoie and Selkoe 2003). 
CD44 is a major adhesion molecule for extracellular matrix components and it is 
implicated in a wide variety of physiological and pathological processes including 
regulation of tumor cell growth and metastasis. CD44 undergoes sequential 
proteolytical cleavages in extracellular and transmembrane domains, and the cleavage 
product derived from CD44 intramembranous cleavage acts as a signal transduction 
molecule. Murakami and coworkers (2003) showed recently that the underlying 
mechanism of the intramembranous cleavage of CD44 is performed by γ-secretase. 
These findings suggest that γ-secretase may have an important role in CD44-dependent 
signal transduction and in functional regulation of adhesion molecules (Murakami et al. 
2003). 
Nectin-1 is a member of the immunoglobulin superfamily and a Ca2+-independent 
adherens junction protein involved in synapse formation. Nectin-1α interacts with N-
terminal fragment of PSEN-1. It undergoes intramembrane proteolytic processing 
analogous to that of APP, mediated by γ-secretase-like activity, resulting in generation 
of a 24-kDa nectin-1α intracellular domain. Similar to nectin-1, other members of the 
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immunoglobulin superfamily involved in synapse formation may also serve as 
substrates for γ-secretase-like intramembrane proteolytic activity (Kim et al. 2002). 
Epithelial (E-) and neural (N-)-cadherins are cell-cell adhesion receptors involved in the 
development, maintenance and function of most tissues, and they play important roles in 
cell signaling, proliferation and differentiation (Steinberg and McNutt 1999, McNeill 
2000, Tepass et al. 2000). E- and N-cadherins are cleaved with γ-secretase-like activity. 
The γ-secretase cleavage dissociates E-cadherins, β-catenins and α-catenins from the 
cytoskeleton, promoting the disassembly of the E-cadherin-catenin adhesion complex. 
Cleavage releases cytoplasmic E-cadherin to the cytosol and increases the levels of 
soluble β- and α-catenins, thus increasing the cytosolic pool of β-catenins, a key 
regulator of Wnt signaling (Marambaud et al. 2002). γ-Secretase cleavage of N-cadherin 
releases the C-terminal fragment that promotes degradation of transcriptional co-
activator CREB binding protein (CBP), and downregulates CBP function (Marambaud 
et al. 2003). In the same study, it was found that PSEN-1 mutations of familial AD fail 
to generate the C-terminal fragment of N-cadherin leading to up-regulation of CRE-
dependent transactivation. FAD-mutation induced transcriptional abnormalities may be 
causally related to the dementia in FAD (Marambaud et al. 2002).  
ErbB4, a transmembrane tyrosine kinase receptor for neuregulins regulating cell 
proliferation and differentiation, is a substrate for presenilin-dependent γ-secretase (Ni 
et al. 2001). Constitutive ectodomain shedding of full-length ErbB4 yields an 
approximately 80 kDa membrane-associated C-terminal fragment (B4-CTF). 
Subsequent intramembrane cleavage of B4-CTF into a soluble intracellular domain of 
ErbB4 (B4-ICD) is inhibited in cells devoid of functional presenilins or by treatment of 
cells with a γ-secretase inhibitor, leading to enhanced accumulation of B4-CTF. The 
soluble B4-ICD functions in the nucleus presumably at the transcriptional level, and 
thus ErbB4 represents the first receptor tyrosine kinase found to undergo intramembrane 
proteolysis and it may mediate a novel signaling function independent of its canonical 
role as a receptor tyrosine kinase (Lee et al. 2002).  
Deleted in colorectal cancer (DCC), p75 and low density lipoprotein receptor-related 
protein (LRP) are also substrates for PSEN-dependent γ-secretase cleavage, resulting in 
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release of their intracellular domains (ICD) (May et al. 2002, Jung et al. 2003, Kanning 
et al. 2003, Taniguchi et al. 2003). DCC may perform dual roles first as a cell surface 
receptor that modulates intracellular signaling pathways and second as a transcriptional 
coactivator that relies on γ-secretase-dependent production and nuclear translocation of 
cytoplasmic domain. γ-Secretase-mediated p75 proteolysis plays a role in the 
formation/disassembly of the p75-TrkA receptor complex by regulating the availability 
of p75 transmembrane domain that is required for this interaction (Jung et al. 2003). 
LRP is a multifunctional cell surface receptor that interacts through its cytoplasmic tail 
with adaptor and scaffold proteins that participate in cellular signaling. The γ-secretase 
cleavage resulting in the release of cytoplasmic domain is indicative of a novel role for 
the intracellular domain of LRP that may involve subcellular translocation of 
preassembled signaling complexes from plasma membrane (May et al. 2002).  
2.4. Susceptibility genes involved in AD 
2.4.1. Apolipoprotein E gene (APOE) 
Apolipoprotein E (ApoE) is a polymorphic lipid transport protein present in liver-
synthesized very low density lipoproteins (VLDL) and high density lipoprotein (HDL) 
(Weisgraber 1994). ApoE mediates the cellular uptake of lipoprotein particles through 
binding to low density lipoprotein receptor (LDLR) and LDLR-related protein (Mahley 
1988). ApoE protein exists in three common isoforms (E2, E3 and E4) encoded by three 
alleles (ε2, ε3 and ε4) of the APOE gene in chromosome 19q13.2 (Emi et al. 1988). In 
most Caucasian populations, ε3 is the most common allele (78%), while ε2 (8%) and ε4 
(14%) are considered variants (Utermann et al. 1980), although the allele distribution 
varies in different ethnic populations. The alleles code for apoE proteins differing at 
amino acid positions 112 and 158; ε2 has a cysteine in both positions, ε3 has cysteine 
and arginine, and ε4 has two arginines (Zannis et al. 1993).  
The ε4 allele of APOE gene is a putative susceptibility factor for aggressive multiple 
sclerosis (Evangelou et al. 1999, Chapman et al. 2001) and coronary heart disease 
(Wilson et al. 1994). The ε4 allele was also found to be a risk factor for early- and late-
onset familial and sporadic AD acting in a dose-dependent manner, and it is linked to an 
earlier onset of AD (Corder et al. 1993, Saunders et al. 1993, Chartier-Harlin et al. 
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1994, van Duijn et al. 1994, Rao et al. 1996). Brain apoE is synthesized in astrocytes 
and microglia, and in AD, apoE immunoreactivity is detected in senile plaques, NFTs 
and cerebrovascular amyloid (Namba et al. 1991). APOE ε4 carriers have more senile 
plaques (Rebeck et al. 1993), NFTs (Ohm et al. 1995) and more severe cholinergic 
deficits (Soininen et al. 1995a, Soininen et al. 1995b) than non-carriers. The APOE 
genotype specific effects on Alzheimer's disease vary according to age and sex; the ε4 
allele has a stronger risk effect in men, and the ε2 allele confers a protective effect only 
in less elderly people (Qiu et al. 2004).  
In response to neuronal damage, apoE production increases to allow a redistribution of 
lipid breakdown products and cholesterol during neuronal regeneration (Ignatius et al. 
1986, Boyles et al. 1989), and the ε4 allele seems to be detrimental to efficient recovery 
after head trauma as well as after intracerebral haemorrhage, since ε4 allele carriers 
have higher mortality and poorer recovery rate than ε3 carriers (Alberts et al. 1995). 
ApoE4 may also impair cognition in stroke patients (Slooter et al. 1997).  
Although APOE is an established risk factor for AD, the exact role of apoE in the 
pathogenesis of AD still remains to be unraveled. There are two popular hypotheses 
concerning the role of apoE in the aetiology of AD. According to the intracellular 
model, apoE4 may not bind tau as well as apoE3, leading to microtubule destabilization 
and formation of NFTs. The extracellular model hypothesizes that apoE4 may bind Aβ 
more readily than apoE3, and this facilitates the deposition of amyloid in plaques.  
The extracellular model is supported by the finding that human apoE forms complexes 
with synthetic Aβ peptide, and moreover, complex formation occurs within minutes 
with apoE4 and Aβ, compared to the hours needed with apoE3 and Aβ (Strittmatter et 
al. 1993). ApoE3 and apoE4 both interact with Aβ peptide to form novel monofibrillar 
structures, although the Aβ monofibrils appear earlier with apoE4 than with apoE3, 
which is consistent with the biochemical and genetic association between apoE4 and 
Alzheimer's disease (Sanan et al. 1994). Furthermore, a body of evidence suggests that 
one major mechanism underlying the connection between apoE and both AD and 
cerebral amyloid angiopathy (CAA) is related to the ability of apoE to interact with Aβ 
peptide, influencing its clearance, aggregation, and conformation. In addition to a 
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number of in vitro studies supporting this concept, in vivo studies with APP transgenic 
mice indicate that apoE and a related molecule, clusterin (apolipoprotein J), have 
profound effects on the onset of Aβ deposition, as well as on the local toxicity 
associated with Aβ deposits both in the brain parenchyma and in cerebral blood vessels 
(Holtzman 2004). One convincing piece of evidence favoring the extracellular model is 
the observation that lack of apoE dramatically reduces Aβ deposition in a transgenic 
model of AD (Bales et al. 1997).  
The intracellular model is supported by findings according to which apoE4 is associated 
with microtubule depolymerization and apoE4 also inhibits neurite outgrowth (Nathan 
et al. 1995), whereas apoE3 promotes neurite sprouting and extension and binds tau 
regions which appear to promote self-assembly of tau into PHF. The binding of apoE3 
to the microtubule-binding repeat region of tau possibly prevents tau phosphorylation 
and incorporation into NFTs (Strittmatter et al. 1994, Nathan et al. 1995). In addition, 
C-terminal-truncated forms of apoE occurring in AD brains and cultured neurons induce 
intracellular NFT-like inclusions in neurons. Furthermore, apoE4 is more susceptible to 
truncation than apoE3, resulting in a much greater intracellular inclusion formation, 
suggesting that apoE4 preferentially undergoes intracellular processing, and creates a 
bioactive fragment that interacts with cytoskeletal components and induces NFT-like 
inclusions in neurons (Huang et al. 2001).  
On the other hand, apoE4 may lack the properties of apoE3, and it has been suggested 
that is not the presence of apoE4, but rather the lack of the other apoE isoforms that 
leads to the increased predisposition to AD (Strittmatter et al. 1994). Consistent with 
this, apoE3 is hypothesized to provide a dose-dependent protective effect against Aβ 
deposition (DeMattos 2004). 
2.4.2. Insulin degrading enzyme and neprilysin: Aβ degrading enzymes 
One hypothesis suggested to be behind the process of AD, is that there is an imbalance 
between Aβ production and clearance (Hardy and Selkoe 2002). Therefore, reducing 
Aβ production or accelerating its clearance from brain have been proposed as 
therapeutic targets against AD (Glabe 2000, Iwata et al. 2000). Insulin degrading 
enzyme (IDE) and neprilysin (NEP) are novel genes associated to AD – these proteins 
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possess the biological function of degrading Aβ, and overexpression of either of these 
two genes retards or completely prevents amyloid plaque formation in transgenic mouse 
models, indicating that they may represent an efficacious therapeutic approach in 
preventing the pathological changes characteristic of AD (Leissring et al. 2003). 
NEP or membrane metallo-endopeptidase (MME, CD10) in chromosome three is a zinc 
metallopeptidase constitutively expressed in various tissues. NEP is important in 
destruction of opioid peptides by cleaving Gly-Phe bonds. It also cleaves at amino 
groups of hydrophobic residues in insulin, casein, hemoglobin, and a number of other 
proteins and polypeptides. In addition, NEP has recently been shown to degrade Aβ 
(Iwata et al. 2000), and its expression is down-regulated in neurons of wildtype and 
transgenic, APPswe expressing mice as a result of aging (Iwata et al. 2002, Apelt et al. 
2003) as well as in affected areas of AD brains (Akiyama et al. 2001). Inhibiting the 
peptidase function of NEP leads to deposition of Aβ42 in the brain (Iwata et al. 2000). 
Injecting Aβ42 into the brains of young mice leads to an up-regulation of endogenous 
NEP expression, reduction of Aβ levels and delayed amyloid plaque deposition 
(Mohajeri et al. 2002), while in aged mice, NEP expression is increased but not capable 
of reducing brain Aβ concentrations or removing pre-existing brain amyloid plaques 
(Mohajeri et al. 2004). Therefore, NEP may be effective early in the course of AD, 
when brain Aβ is found at a higher degree in soluble rather than in aggregated form 
(Mohajeri et al. 2004). Thus, the biological activity of NEP might be affected by 
amyloidogenic factors during aging. In most familial early-onset AD cases, Aβ 
accumulation is caused by an increase in Aβ42 production (Scheuner et al. 1996, Hardy 
1997), while in sporadic late-onset AD there does not seem to be any overproduction of 
Aβ42 (Scheuner et al. 1996) and therefore, aging-associated reduction of Aβ clearance 
is a candidate mechanism accounting for the accumulation of Aβ in aging brain. In 
support of  this theory, late-onset AD has been associated with a repeat polymorphism 
in the promoter region of NEP gene (Sakai et al. 2004), which might cause or be in 
linkage disequilibrium with another polymorphism with a functional effect on the NEP 
transcription rate.  
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IDE or insulysin, a cytosolic metalloendoprotease that degrades insulin, glucagon and 
other polypeptides, is involved in insulin metabolism. In 1994, IDE was found to 
degrade Aβ (Kurochkin and Goto 1994), thus preventing the accumulation of 
amyloidogenic derivatives (McDermott and Gibson 1997). The interaction between 
insulin and Aβ was demonstrated by the observation that excess insulin inhibited the 
degradation of Aβ nearly completely, and Aβ inhibited insulin degradation in a dose-
dependent manner. In addition, IDE activity is considerably lower in the cytosolic 
fraction of AD brains compared to controls (Perez et al. 2000), possibly reflecting the 
findings of stronger neuronal IDE immunostaining in AD brains compared to controls. 
The staining is particularly found in neurons associated with senile plaques (Bernstein et 
al. 1999), indicating the abnormal localization of IDE with insoluble compartments 
(Perez et al. 2000). At the same time, IDE activity in insulin degradation is less 
extensively decreased than in Aβ degradation, suggesting that the metabolic 
abnormalities in AD cells change the affinity of IDE for its substrates (Perez et al. 2000, 
Hoyer 2002). Alternatively, the decreased activity of IDE may be related to the cell loss 
in AD brains. Therefore, it is a matter of debate whether the lower IDE activity in AD 
brain is a primary defect or a result of  neurodegenerative processes (Perez et al. 2000). 
IDE interacts with Aβ residues 17-24 (McDermott and Gibson 1997), which are also 
crucial to the formation of amyloid fibrils (Soto et al. 1995). Missense mutations in IDE 
that cause partial loss of function, result in decreased catalytic activity of IDE and a 
deficit in the degradation of both insulin and Aβ, sufficient to cause type 2 diabetes 
mellitus, and possibly, to increase the risk of AD (Farris et al. 2004).  
Impaired glucose and energy metabolism as such are characteristic for sporadic AD, and 
it has even been suggested that formation of amyloidogenic derivatives and 
hyperphosphorylation of tau are merely a consequence of reduced neuronal activity 
deriving from the deficit of neuronal glucose and energy metabolism (Hoyer 2002). The 
abnormal neuronal glucose metabolism is supposedly caused by a disturbance in the 
insulin signal transduction, whereas in AD, insulin receptor density is upregulated, 
indicating desensitization of neuronal insulin receptors (Frolich et al. 1998, Hoyer 
1998). Impaired cerebral glucose metabolism leads to a decline in acetyl-CoA (Perry et 
al. 1980) and in acetylcholine concentrations (Sims et al. 1983), which in turn leads to a 
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degeneration of the  cholinergic system correlating with the progress of disturbed 
mental capabilities in AD patients (Baskin et al. 1999, Davis et al. 1999). ATP 
production is also diminished, leading to an energy deficit that progresses during the 
course of disease (Hoyer 1992). Reduction of insulin and ATP attenuates the secretion 
of neuroprotective sAPP (Gasparini et al. 1997, Gasparini et al. 1999, Hoyer 2002), 
increases the secretion of Aβ (Gabuzda et al. 1994), and activity of protein kinases that 
hyperphosphorylate tau (Roder and Ingram 1991, Bush et al. 1995, Hong and Lee 
1997). In addition, insulin resistance has recently been shown to promote amyloidosis in 
a mouse model of AD (Ho et al. 2004), and moreover, decreased hippocampal glucose 
metabolism and spatial memory impairment are associated with Aβ deposition in 
APP/PSEN-1 transgenic mice (Sadowski et al. 2004). The decreased insulin receptor 
(IR) mediated transduction, as a consequence of insulin resistance, might mediate this 
function through decreased IR beta subunit autophosphorylation and reduced 
phosphatidylinositol-3 kinase to increase GSK-3α activity, which in turn promotes Aβ 
generation. Thus, insulin resistance may be connected to mechanisms responsible for 
developing AD, and IR signaling may underlie the Aβ production in the brain (Ho et al. 
2004).   
Based on functional grounds, IDE is a noteworthy candidate gene of AD. Furthermore, 
IDE is within or near the chromosome 10 locus identified in family-based linkage-
studies of AD (Bertram et al. 2000, Myers et al. 2000). Subsequently IDE has been 
associated to AD in numerous SNP and haplotype studies (Ait-Ghezala et al. 2002, 
Prince et al. 2003, Ertekin-Taner et al. 2004), and in particular to AD in patients without 
the APOE ε4 allele (Edland et al. 2003, Edland 2004). The associated polymorphisms in 
the promoter region might affect the expression levels of IDE or perhaps intronic 
variants can affect the post-transcriptional processing and expression levels of splice 
variants (Edland et al. 2003). Alternatively, the associated polymorphisms may be in 
linkage disequilibrium with another, yet unidentified, variant of IDE or on a 
neighboring gene (Prince et al. 2003). 
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2.5. Mapping of novel AD genes 
2.5.1. Population choice in complex disease gene mapping 
In order to map genes underlying complex diseases like AD, genetic isolates with a 
history of a small founder population, long-lasting isolation and population bottlenecks 
have been increasingly used, since they are valuable resources in the identification of 
disease genes (Peltonen 2000). The main advantage of genetic isolates is that in genes 
behind complex diseases there should be less variability (fewer disease disposing alleles 
and fewer influencing genes), and therefore, the isolates could be useful in association-
based mapping studies (Jorde et al. 2000). The Finnish population has been especially 
notable in the application of linkage disequilibrium approaches, largely because of its 
small founding size and limited admixture (Jorde et al. 2000) shown by extreme locus 
and allelic homogeneity of monogenic Finnish disease heritage disorders (Peltonen 
2000). Particularly the Finnish population in the late settlement area in the eastern and 
northern part of Finland is only 300-400 years, or 15-20 generations of age (Peltonen 
2000), and the relatively young age of Finnish population means that this the population 
is useful in the initial localization of  disease-causing genes to relatively large 
chromosomal regions due to larger regions of linkage disequilibrium (Jorde et al. 2000). 
The age of the Finnish population is also young enough for  disease-causing mutation to 
be associated with a specific background haplotype, but old enough for recombinations 
to decrease disequilibrium between the mutation and less closely linked markers (Jorde 
1995).  
2.5.2. Single nucleotide polymorphisms and candidate gene association studies 
More than five million single nucleotide polymorphisms (SNPs) (one per 600 bp) with a 
minor allele frequency greater than 10% are expected to exist in the human genome 
(Kruglyak and Nickerson 2001). Compared to mutations, whose frequency is below 1% 
in a population, SNPs are very polymorphic and because of their polymorphic nature, 
SNPs can be utilized in the search of genes predisposing to multifactorial diseases. 
SNPs are likely more useful for population association studies than microsatellite 
markers as a result of their much higher density in the genome and much greater 
mutational stability (Ardlie et al. 2002). On the other hand, instead of single SNPs or 
SNP haplotypes, highly polymorphic microsatellite markers can provide much greater 
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power for detecting intermarker LD, emphasizing the importance of careful marker 
selection when designing a LD study (Varilo et al. 2003). 
In the search of susceptibility genes for single gene disorders, linkage analysis or 
positional cloning, where the whole genome of affected family members is scanned, 
have been widely applied (Kwon and Goate 2000, Daly and Day 2001). A candidate 
gene approach, where the association between an allele or alleles of a candidate gene 
and a disease is studied, has been suggested to be better suited for detecting genes 
underlying common complex disorders where the risk associated with a given candidate 
gene is relatively small (Risch and Merikangas 1996). One clear advantage of 
association studies compared to linkage-based approaches is the large number of cases 
and controls that are more easily obtained compared to trying to locate families with 
multiple affected members (Kwon and Goate 2000).  
Choosing a potential candidate gene involves an educated guess and the understanding 
of the mechanisms underlying the disease studied. Another approach is to choose 
candidate gene based on its localization in genomic region that has been linked to the 
disease in a genome wide search. A polymorphic site chosen within the gene may 
represent a possible functional SNP causing a change in protein function via amino acid 
substitution, in gene activity by affecting gene transcription, RNA splicing, mRNA 
stability and mRNA translation or it may be associated to deletion or insertion resulting 
in a frameshift in the coding region and complete deletion of the gene (Daly and Day 
2001). Possibly, the SNP has no known functional significance, however, noncoding 
SNP in intron or outside the gene may also be associated with altered phenotype, if it is 
located close to functional SNP (typically within 200 kb) or other change in nearby 
genomic region, and is inherited together or is in linkage disequilibrium with the 
functional SNP (Kwon and Goate 2000).  
Polymorphisms with functional consequences should be considered as high priority, 
because most likely they affect the function of the protein, and therefore might be 
involved in disease aetiology (Tabor et al. 2002). However, such polymorphisms are 
expected to have low allele frequencies and, in fact, the majority of coding region SNPs 
(cSNPs) that change an amino acid have allele frequencies below 5% (Cargill et al. 
1999, Halushka et al. 1999). SNPs with very low allele frequencies should have very 
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large relative risks associated with them, if they are to be detected in an association 
study, and therefore, SNPs with allele frequencies of at least 5% are generally more 
likely to be useful in association studies. Thus using polymorphisms with less severe 
functional effects might be advisable (Tabor et al. 2002). The estimates that there are 
approximately 30,000 genes in the human genome (Ewing and Green 2000, Roest 
Crollius et al. 2000, Lander et al. 2001), point to the existence of a total of 
approximately 120,000 cSNPs. Of these, 40% are expected to change an amino acid 
(Cargill et al. 1999, Halushka et al. 1999). These 50,000 non-synonymous cSNPs, 
together with an unknown number of regulatory and other non-coding but functional 
polymorphisms, comprise the bulk of common molecular variation with potential 
phenotypic consequences (Kruglyak and Nickerson 2001). In the future, genotyping this 
complete set of functional variants will be a minimal requirement for direct association 
studies (Lander 1996, Risch and Merikangas 1996, Collins et al. 1997).  
Candidate gene association studies have pitfalls that should be considered when 
designing any study. A major drawback in testing candidate SNPs directly is the fact 
that lack of association with candidate SNP does not rule out functionally important 
changes at nearby SNPs, except those that are in LD with the candidate SNP (Carlson et 
al. 2004b). A problem of case-control design is the inappropriate matching of cases and 
controls with respect to demographic factors, such as age, gender and genetic 
background which may result in false associations (Kwon and Goate 2000, Daly and 
Day 2001). From the statistical viewpoint, genotyping a number of candidate genes and 
polymorphisms in the same population of cases and controls increases the chance of 
false associations due to multiple testing. Bonferroni correction (multiplying the p-value 
with the number of tests performed) has been applied, but the conservative nature of this 
correction may also lead to loss of genuine associations. The requirement of Bonferroni 
correction has been debated in cases where the candidate gene has a clear biological 
relevance to the disease and the chosen polymorphism has a proven functional 
significance (Perneger 1998, Daly and Day 2001). Another problem arises from 
interactions between polymorphisms in multiple loci that have been modelled with 
several possible epistatic models, such as synergistic, antagonistic, balanced or 
permissive epistatic interactions. The number of gene-gene or gene-environment 
interactions is enormous, and because of the sheer number of potential interactions, no 
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comprehensive search has the power to detect them all. There are several reasonable 
approaches to reduce the interactions analyzed for example, to limit analysis to 
biologically plausible interactions between genes in related pathways or to markers with 
an appreciable single-locus effect, given that risk interactions are more reasonable 
between genes in a physical interaction, in the same pathway or in the same regulatory 
network  (Carlson et al. 2004a).  
2.5.3. Linkage disequilibrium 
The genetic complexity underlying common diseases is largely unknown, and the 
unmapped susceptibility genes behind common complex disorders with genetic 
components have only a scant prospect of being identified using current technologies 
such as linkage and linkage disequilibrium analysis (Wright et al. 1999). Linkage 
analysis using independent pedigrees has a limited power to detect genes with 
intermediate or small effects on common diseases, while association methods have a 
greater power to detect such effects (Jorde 1995, Risch and Merikangas 1996). Linkage 
disequilibrium (LD) is found when alleles of different loci are inherited together more 
often than would be expected based on their frequencies, and it measures the co-
segregation of alleles in a population, when linkage measures the co-segregation in a 
pedigree. The key factors influencing the LD are the recombination frequency and the 
number of generations after introduction of the mutation or the age of the mutation. LD 
around an allele arises because of selection or population history, small population size, 
genetic drift or population mixture, and decays owing to rapid population growth 
reducing the genetic drift and recombination breaking down ancestral haplotypes (Hartl 
and Clark 1997). 
LD mapping relies on the assumption that a single ancestral mutation is responsible for 
a large proportion of disease cases in the present-day population, and LD mapping in 
the population has an increased power to detect genes with intermediate or small effects 
on common diseases, but the power is limited by the amount of allelic heterogeneity 
(Terwilliger and Weiss 1998). 
As a measure of LD, several variables are used (Lewontin 1964, Devlin and Risch 
1995). One of the earliest measures of LD, symbolized by D, quantifies disequilibrium 
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as the difference between the observed frequency of a two-locus haplotype (PAB, for 
alleles A and B) and the frequency it would be expected to show if the alleles were 
segregating at random (PA x PB).  
D = PAB - PA x PB. 
Alternative measures of LD are the absolute values of r2 and D’ defined by  
D’ = D/Dmax. 
D’ = 1 is known as complete LD, when two markers have not been separated by 
recombination, and values of D’ < 1 indicate that the complete ancestral LD has been 
disrupted during the history of the sample.  
Considerable variation has been found in the pattern and extent of LD, resulting in a 
debate concerning the average extent of levels of LD useful for association mapping 
(Ardlie et al. 2002). For northern European populations, a range of 10-30 kb of LD has 
been proposed, but due to a tremendous variation in the extent of LD from one region of 
the genome to another, relying on the average extent of LD when designing an 
association mapping study might be considered as risky (Ardlie et al. 2002). 
Full-genome linkage and association analysis have been used to detect novel 
susceptibility regions for AD, and in future we will know whether any candidate gene of 
these susceptibility regions shows consistent evidence for AD association in various 
populations (table 3). 
2.5.4. Haplotype blocks 
LD patterns vary across the human genome with some regions of high LD interspersed 
by regions of low LD (Daly et al. 2001, Johnson et al. 2001, Patil et al. 2001, Dawson et 
al. 2002, Gabriel et al. 2002). Thus it has been suggested that the human genome can be 
arranged into block-like patterns of LD, referred to as haplotype blocks, with low 
between block recombination frequency (Daly et al. 2001, Jeffreys et al. 2001, Reich et 
al. 2001, Wang et al. 2002). In these regions of strong LD, only a few common 
haplotypes (the arrangement of genetic polymorphisms within a single chromosome) are 
found. The haplotype blocks may extend up to 100 kb regions in which almost no 
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Table 3. Linkage and association regions observed in full-genome screens, and potential candidate genes 
locating at the regions according to Bertram and Tanzi, 2004. 
Chromosomal 
location  
Study Candidate 
genes 
Relevance to AD pathogenesis 
Early-onset loci    
11q25 (Blacker et al. 2003) BACE β-cleavage of Aβ 
19q13 (Blacker et al. 2003) PEN-2/ 
GSK3A 
Component of γ-secretase complex/ 
APP processing and tau 
phosphorylation 
Late-onset loci    
1p36 (Kehoe et al. 1999, 
Hiltunen et al. 2001, 
Myers et al. 2002) 
MTHFR Homocysteine metabolism 
4q35 (Li et al. 2002,  
Blacker et al. 2003) 
SNCA Tau fibrillization, 
component of Aβ plaques 
5p13-15 (Kehoe et al. 1999, 
Pericak-Vance et al. 2000, 
Hiltunen et al. 2001, 
Myers et al. 2002,  
Blacker et al. 2003) 
-  
6p21 (Kehoe et al. 1999, 
Hiltunen et al. 2001, 
Myers et al. 2002,  
Blacker et al. 2003) 
TNFA 
HLA-A2 
Inflammation and apoptosis 
Inflammation 
6q22 (Pericak-Vance et al. 1997, 
Kehoe et al. 1999,  
Myers et al. 2002) 
ESRA Estrogen mediated actions 
9p21 (Kehoe et al. 1999, 
Pericak-Vance et al. 2000, 
Myers et al. 2002) 
VLDL-R Cholesterol metabolism 
9q22 (Kehoe et al. 1999, 
 Myers et al. 2002,  
Blacker et al. 2003) 
ABCA1 Brain cholesterol metabolism 
10q21-22 (Kehoe et al. 1999, 
 Myers et al. 2002) 
HHEX Hematopoietically expressed 
homeobox 
10q24-25 (Li et al. 2002,  
Blacker et al. 2003) 
IDE 
PLAU 
KNSL1 
Degradation of Aβ 
Degradation of Aβ ? 
Thyroid receptor interacting protein 
12p11 (Pericak-Vance et al. 1997, 
Kehoe et al. 1999, 
 Myers et al. 2002) 
A2M 
LRP 
TFCP2 
Aβ catabolism 
Internalization of APP and Aβ 
Transcription factor 
19q13 (Zubenko et al. 1998, 
Kehoe et al. 1999,  
Pericak-Vance et al. 2000, 
Myers et al. 2002,  
Blacker et al. 2003) 
APOE Aβ aggregation 
Xp21 (Kehoe et al. 1999,  
Myers et al. 2002,  
Blacker et al. 2003) 
MAOA Metabolism of neuroactive and 
vasoactive amines 
Xq21-26 (Zubenko et al. 1998, 
Kehoe et al. 1999,  
Myers et al. 2002) 
-  
- No potential candidate gene assessed. 
recombination takes place, being separated by recombination hot-spots (Patil et al. 
2001). Therefore, the human genome can be partitioned into blocks with limited 
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haplotype diversity, so that only a small fraction of the SNPs captures most haplotypes 
(Zhang et al. 2002). Using these haplotype tagging SNPs (htSNPs) that are sufficient to 
capture most of the haplotype structure of the human genome with a block structure 
(Johnson et al. 2001, Patil et al. 2001) makes the genome-wide association studies more 
feasible (Daly et al. 2001, Johnson et al. 2001). Using htSNPs forming only 25% of all 
the SNPs, the power to find an association is reduced by 4%, compared to an approach 
using a comparable number of randomly chosen SNPs, where the power loss is 12%. At 
least two human chromosomes (chromosomes 21 and 22) seem to show this kind of 
block-like structure (Patil et al. 2001, Dawson et al. 2002). 
Although htSNPs are superior to randomly selected SNPs, LD-selected tagSNPs 
describe more comprehensively common patterns of variation with more 
straightforward interpretation of the results (Carlson et al. 2003). To genotype only the 
minimal amount of SNPs, rational selection of SNP sites providing maximal 
information about common variations in genomic region is possible on the basis of the 
observed pattern of LD between common SNPs. In Americans originating from Europe, 
covering all genomic regions would mean genotyping of 4.2 tagSNPs per 10 kb, and 
extrapolating this to 35 000 genes with an average of 27 kb, genotyping of 400 000 
SNPs would be required if one wished to resolve over 80% of all existing haplotypes 
(Carlson et al. 2004b). However, because an appreciable fraction of all common 
variants is either private or common only in a single population, a subset of SNPs 
required to detect disease associations should be selected specifically for each 
population with a different demographic history (Wang et al. 2002, Carlson et al. 2003). 
2.6. CYP19 
2.6.1. Aromatase enzyme 
Aromatase enzyme, a product of the CYP19 gene, catalyzes the formation of estrone 
and estradiol from C19 androgens, androstenedione and testosterone (figure 4) in a series 
of reactions leading to formation of the phenolic A ring characteristic of estrogens. In 
most mammals, aromatase is expressed only in gonads and brain, whereas primates 
express the gene in additional extragonadal sites (Simpson et al. 1994). Estrogen 
synthezised in extragonadal sites acts predominantly at the local tissue level in a 
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paracrine or intracrine fashion (Labrie et al. 1998). The total amount of estrogen 
synthezised at these sites may be minute, but the local tissue concentrations achieved 
are probably high and exert biological influence locally. Thus extragonadal estrogen 
biosynthesis plays an essential but thus far mostly unrecognized, physiological and 
pathophysiological role (Simpson and Davis 2001). 
In brain, the aromatase enzyme is expressed in neurons, astrocytes and glial cells 
(Zwain and Yen 1999, Ishunina et al. 2005), and it is present mainly in brain regions 
involved in the control of reproductive functions, such as the hypothalamus, the preoptic 
area and the limbic system (Roselli and Resko 1993, Abdelgadir et al. 1994), where 
aromatization of androgens is required for the sexual differentation of the developing 
brain (MacLusky and Naftolin 1981), and for the display of male sexual behavior 
(Clancy et al. 1995). In primates, aromatization mediates the effects of testosterone on 
gonadotrophin secretion as a part of the feedback mechanism (Ellinwood et al. 1984), 
but in addition to this effect, the local formation of estrogens in adult brain may be 
involved in modulating cognitive processes or altering aging by mechanisms currently 
unknown (Lephart 1996).  
 
Figure 4. Current knowledge concerning the biochemical pathways of neurosteroidogenesis. Biochemical 
reactions indicated by arrows have been demonstrated by measuring the biological activity of the enzyme 
in neural tissue and the localization of the enzyme by immunohistochemistry or its mRNA in situ 
hybridization in the nervous system with the exception of 21-hydroxylase for which only expression of its 
mRNA has been shown. (Zwain and Yen 1999, Stoffel-Wagner 2001).  
Aromatase enzyme of P450 cytochrome superfamily is encoded by CYP19 gene on 
chromosome 15q21.1. The coding region of CYP19 gene is 30 kb in size spanning nine 
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exons of which exon II is the first translated exon. Upstream of exon II are a number of 
alternative first exons that are spliced into the 5’-untranslated region of the transcript in 
a tissue-specific fashion. For example, placental transcripts contain at their 5’-end a 
distal exon I.1 that is driven by powerful promoter upstream of exon I.1 (Means et al. 
1991). On the other hand, transcripts of ovaries, testes, adipose tissue and endometric 
plaques contain promoter II-specific exonic sequence, which is immediately upstream 
of the translational start site (Zeitoun et al. 1999). Osteoblast transcripts contain yet 
another distal exon (I.4) downstream of exon I.1 (Mahendroo et al. 1993), and in 
addition, brain have their own first exon (I.f) (Honda et al. 1994). Splicing of these 
untranslated exons to form the mature transcript occurs at a common 3’-splice junction 
that is upstream of the translational start site. The presence of regulatory region of 93 kb 
with a number of alternative first exons indicates that although transcripts of different 
tissues have different 5’-termini, the coding region and thus the protein expressed in 
various tissue sites is always the same. However, the promoter regions upstream of each 
of the several untranslated first exons have different cohorts of response elements, and 
so the regulation of aromatase expression and estrogen biosynthesis in each tissue is 
unique (Simpson et al. 1997).  
The brain-specific exon I.f promoter region contains a potential androgen/glucocorticoid 
binding site (Honda et al. 1994), and furthermore, aromatase mRNA may contain an 
estrogen responsive element, that might stabilize the aromatase mRNA and increase 
CYP19 gene expression (Harada et al. 1993, Bourguiba et al. 2003). Indeed, there is 
large body of evidence that aromatase is regulated by both its substrates, aromatizable 
androgens, and by its endproduct, estradiol, at least partly at the translational level 
(Wagner and Morrell 1996, Balthazart et al. 2003). Furthermore, aromatase activity and 
mRNA are influenced by castration and ovariectomy and aromatizable androgens and 
estrogen (Yamada et al. 1993, Dellovade et al. 1994, Roselli et al. 1998, Balthazart et al. 
2003). Tissue-specific and brain region-dependent expression of aromatase may be 
regulated by different tissue- and site-specific promoters employing different signalling 
pathways and different transcription factors including more than sex steroids (Simpson 
and Davis 2001, Ishunina et al. 2005).  Additionally, locally produced neurosteroids 
may diffuse from other brain regions and contribute to the regulation of aromatase 
expression (Balthazart et al. 2003). 
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2.6.2. Estrogens and AD 
A gender-related difference has been related to the risk of AD; prevalence rates of AD 
are higher in women than men, irrespective of age (Fratiglioni et al. 1997). In 
premenopausal women, the ovaries are the principal source of estradiol, which functions 
as a circulating hormone to act on distal target tissues. However, in postmenopause the 
ovaries cease to produce estrogens with the plasma estrogen levels decreasing 
dramatically (Van Beek et al. 2004), and under these circumstances, estradiol is no 
longer solely an endocrine factor; instead it is produced in a number of extragonadal 
sites and acts  locally as a paracrine or intracrine factor (Labrie et al. 1998). The 
plummeting estrogen levels might increase the risk of developing AD in 
postmenopausal women compared to age-matched men (Paganini-Hill and Henderson 
1994). This hypothesis is also supported by a study which measured lower estrogen 
levels in women with AD compared to age-matched controls (Honjo et al. 1989). The 
increased lifetime risk of dementia for women reflects both the higher life expectancy of 
women and the higher dementia risk at very old age (Ott et al. 1998).  
Estrogens have a variety of beneficial effects on brain functioning; estrogens induce 
neurite outgrowth (Ferreira and Caceres 1991), increase dendritic spine density and 
regulate synaptogenesis (Gould et al. 1990, Murphy and Segal 1996), reduce the 
accumulation of β-amyloid (Xu et al. 1998) and protect neurons from oxidative stress 
(Behl et al. 1995, Goodman et al. 1996). Estrogens may also promote the activity of the 
cholinergic system, reduce cardiovascular risk, and ERT has been claimed to protect 
against cognitive decline and dementia in the elderly (Skoog and Gustafson 1999). In 
addition, estrogens have improved some forms of learning and memory in animal 
studies conducted mainly with mice and rats mimicking the postmenopausal state by 
ovariectomy (O'Neal et al. 1996, Packard and Teather 1997, Heikkinen et al. 2002, Li et 
al. 2004) 
The cellular actions of estrogens are mediated through estrogen receptors (ERs) α and β 
that are expressed throughout the brain, including the brain areas important for learning 
and memory functions, such as the hippocampus (Mitra et al. 2003). ERs are ligand-
activated enhancer proteins that function both as signal transducers and transcription 
factors. The ER subtypes are expressed differentially and tissue-specifically in response 
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to estrogen (Carley et al. 2003, Matthews and Gustafsson 2003). The classical nuclear 
receptor mechanism of gene transcription modulation involves the binding of the 
hormone to its cognate receptor protein, conformational changes of the receptor site and 
altered composition of interacting proteins, allowing the ligand-occupied ER dimer to 
translocate to the nucleus and to bind specific sequences in the promoter region of target 
genes (Beato and Klug 2000). In the direct binding mechanism, the estradiol-ER 
complex binds directly to a specific sequence, the so-called estrogen responsive 
element, and interacts directly with coactivator proteins and components of the RNA 
polymerase II transcription initiation complex resulting in enhanced transcription 
(Klinge 2000). During tethering, the ER interacts with another DNA-bound 
transcription factor stabilizing the transcription factor and recruiting coactivators to the 
complex without ER binding to DNA (Li et al. 2001). The timescale of these actions 
varies from one to several hours.  
In addition to the genomic action, there is a growing body of evidence that estrogens 
can mediate physiological effects through non-genomic or non-classical signaling 
mechanisms that are characterized by their rapid onset from seconds to minutes, and 
their insensitivity to transcriptional inhibitors. These effects are likely to be mediated by 
receptors integrated or associated with the plasma membrane and by an activation of 
distinct intracellular signaling cascades (Falkenstein et al. 2000, Kuppers et al. 2001). It 
is possible that the classical ERα associates with neuronal plasma membrane via MNAR 
(modulator of non-genomic estrogen receptor) protein (Wong et al. 2002) capable of 
phosphorylating members of the MAP kinase family, and mediating these rapid non-
genomic estrogen actions (Beyer et al. 2003). 
2.6.3. Estrogen replacement therapies in AD 
Numerous case-control, cross-sectional and prospective studies (Henderson et al. 1994, 
Paganini-Hill and Henderson 1994, Tang et al. 1996, Kawas et al. 1997, Baldereschi et 
al. 1998, Jacobs et al. 1998, Harwood et al. 1999, Steffens et al. 1999, Waring et al. 
1999) have reported a lower risk of AD and dementia for women receiving 
postmenopausal ERT compared to women without ERT, whereas several prospective 
observational studies (Barrett-Connor and Kritz-Silverstein 1993, Brenner et al. 1994, 
Matthews et al. 1999, Henderson et al. 2000, Mulnard et al. 2000, Wang et al. 2000) 
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have found no protective effect of estrogen on cognition, or the incidence of dementia. 
Four recently conducted meta-analyses assessing the risk of AD and dementia, found a 
protective effect for estrogen use (Yaffe et al. 1998, Hogervorst et al. 2000, LeBlanc et 
al. 2001, Nelson et al. 2002), although the methodological problems of the studies and 
the harmful effects of estrogen use on breast cancer and stroke risk were also 
emphasized. However, a recently conducted randomized, placebo-controlled clinical 
trial demonstrated an adverse effect of the combination of estrogen-progestin on the risk 
of dementia, with no effect on mild cognitive impairment (Shumaker et al. 2003). The 
risk of stroke also increased in women using the combined estrogen-progestin 
preparation, and the hypothesis could be that the increase in the risk of developing 
dementia may primarily be due to an increase in vascular-related dementia, since 
vascular disease often coexists with AD (Snowdon et al. 1997), and silent brain micro-
infarcts increase the risk of dementia (Vermeer et al. 2003). The combination of 
estrogen/progestin may also illustrate the possibility of increased risk of dementia, since 
when used in combination, the synthetic medroxyprogesterone acetate used in the study 
(Shumaker et al. 2003), appears to reverse the positive effects of estrogen alone (Nilsen 
and Brinton 2002a, b, 2003), as also demonstrated in a prospective observational study 
(Rice et al. 2000). Disappointingly, on February 2004, a large randomized, placebo-
controlled clinical trial of estrogen use was also stopped 13 months prior to planned 
study end, because of the increased risk of stroke and no apparent protective effect on 
coronary heart disease (http://www.wfubmc.edu/whims/docs/E-alonePress2-27-
04finalSR.pdf). Until the final results of this study concerning the risks of AD and mild 
cognitive impairment are available, estrogen and progestin in combination should not be 
prescribed with the expectation of enhancing cognitive performance in postmenopausal 
women, since the risks clearly outweigh the benefits (Shumaker et al. 2003). 
2.6.4. Androgens and AD 
Androgens are synthesized in ovary, testes and adrenal gland, and aging diminishes the 
production and serum concentrations of androgens in both genders (Ravaglia et al. 
1996, Burger et al. 2000, Schatzl et al. 2003, Van Beek et al. 2004). In women, aging 
affects more than menopause (Burger et al. 2000, Van Beek et al. 2004), however, 
postmenopausal ERT reduces DHEAS and testosterone concentrations in serum, and in 
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addition, increases circulating steroid hormone binding protein levels, resulting in an 
even more prominent decline of free testosterone (Casson et al. 1997).  
The impact of androgens on cognitive decline in the elderly and molecular mechanisms 
of neurodegeneration are still unclear because of conflicting data (Hogervorst et al. 
2001, Weill-Engerer et al. 2002, Bimonte-Nelson et al. 2003, Tan and Pu 2003, 
Wolkowitz et al. 2003). The information regarding the testosterone levels of men with 
AD compared to healthy control subjects is also controversial (Hogervorst et al. 2001, 
Pennanen et al. 2004). Nevertheless, androgen supplementation by testosterone has been 
shown to improve cognition and visual-spatial skills in hypogonadal aging men (Tan 
and Pu 2003), and working memory of aged male rats (Bimonte-Nelson et al. 2003), but 
the testosterone precursor, dehydroepiandrosterone (DHEA), is incapable of improving 
cognitive performance of subjects with AD (Wolkowitz et al. 2003). Androgen 
receptors and cognitive function have also been associated in a genetic study (Yaffe et 
al. 2003). 
The benefits of androgens on characteristics relevant to AD are clear; androgens prevent 
hyperphosphorylation of tau, a component of NFTs (Papasozomenos 1997, 
Papasozomenos and Shanavas 2002), attenuate β-amyloid toxicity (Pike 2001), 
stimulate the α-secretase pathway resulting in increased sAPPα production 
(Goodenough et al. 2000) and reduced β-amyloid peptide production (Gouras et al. 
2000, Ramsden et al. 2003), increase hippocampal spine synapse density (Leranth et al. 
2004) and protect neurons from oxidative stress (Bastianetto et al. 1999), excitotoxicity 
(Veiga et al. 2003) and against apoptosis (Hammond et al. 2001). However, the 
importance of testosterone aromatization on these effects is still controversial. Several 
studies support the hypothesis of androgens affecting directly through androgen 
receptors (Papasozomenos 1997, Hammond et al. 2001, Pike 2001, Papasozomenos and 
Shanavas 2002, Ramsden et al. 2003), while others have suggested that it is the 
androgens which are aromatized to estrogens that underlie the positive effects of 
androgens (Goodenough et al. 2000, Bimonte-Nelson et al. 2003, Veiga et al. 2003) or 
that both pathways may be involved (Leranth et al. 2004). Androgens have many 
similar neuroprotective effects as estrogens, and it is possible that in postmenopausal 
brain, androgens acting via androgen receptors are the neuroprotective hormones. 
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Testosterone also inhibits early atherogenesis via its aromatization to estradiol (Nathan 
et al. 2001). The risk of coronary artery disease is greater in men than women during the 
reproductive years, but after female menopause, the risk is equal among women and 
men (Nathan and Chaudhuri 1997), implicating that the gender-difference might be 
caused by the attenuating effect of estrogen on atherogenesis (Krempler et al. 1995, 
Rosano and Fini 2002). Since the clinical indicators of atherosclerosis are more frequent 
in individuals with AD than in nondemented individuals (Hofman et al. 1997), the 
conversion of androgens to estrogens might also protect from dementia via the 
protection against atherogenesis.  
2.6.5. CYP19 and AD 
Epidemiological studies suggest a neuroprotective role for estrogen in AD and therefore 
the genetic role of components of estrogen metabolism, as well as α and β estrogen 
receptors, have been studied extensively (Brandi et al. 1999, Forsell et al. 2001, 
Lambert et al. 2001). In brain, local expression of aromatase is involved in regulating 
neural differentiation, plasticity, and sexual behavior through estrogen synthesis 
(Hutchison 1991, Lephart 1996, Mellon et al. 2001, Mellon and Vaudry 2001). 
Aromatase enzyme deficiency in mice increases the vulnerability of hilar neurons to 
neurotoxic agents (Azcoitia et al. 2001), whereas brain injury in mice and rats rapidly 
up-regulates aromatase expression in glial cells at the injury site suggesting that 
aromatase may be involved in the protection of injured neurons through increased 
estrogen levels (Garcia-Segura et al. 1999a, Garcia-Segura et al. 1999b). In songbirds, 
neural aromatization increases the size of hippocampal neurons and improves learning 
(Oberlander et al. 2004). Recent studies also suggest that the brain aromatase encoded 
by CYP19 gene may serve as a target for novel approaches for the treatment of 
neurodegenerative diseases and ischemia (Azcoitia et al. 2001, Azcoitia et al. 2003, 
McCullough et al. 2003). 
The estrogen production in extragonadal sites, such as brain, is dependent on an external 
source of C19 androgenic precursors because these tissues are incapable of converting 
cholesterol to C19 steroids. In postmenopausal women, the circulating testosterone levels 
are an order of magnitude greater than circulating estradiol levels suggesting that 
circulating testosterone levels might be more important for maintaining local estrogen 
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levels in extragonadal sites than are circulating estrogens (Simpson and Davis 2001). 
Moreover in men, circulating testosterone levels are an order of magnitude greater than 
those in postmenopausal women. Thus, the uninterrupted sufficiency of circulating 
testosterone in men throughout life supports the local production of estradiol by 
aromatization of testosterone, affording an ongoing protection against the so-called 
estrogen deficiency diseases, i.e. protecting the bones against mineral loss and possibly 
contributing to the maintenance of cognitive function and prevention of Alzheimer’s 
disease (Simpson et al. 2000). 
 A genome-wide LD mapping study conducted with late-onset AD patients and control 
subjects (Hiltunen et al. 2001) revealed a region of interest on chromosome 15q21.1 
(table 4). Another recent study found also an association between chromosome 15q22 
and AD (Scott et al. 2003). Based on the relatively short distance from the associated 
microsatellite marker D15S659 (Hiltunen et al. 2001) and the possible neuroprotective 
role of estrogens in AD (Paganini-Hill and Henderson 1996, Costa et al. 1999, Waring 
et al. 1999), the CYP19 gene encoding for aromatase could be regarded as a 
susceptibility candidate for AD.  
Table 4. Evidence for linkage/association in chromosome 15q near CYP19 locus observed in full genome 
screens. 
Study Chromosomal 
location 
Marker Linkage/association Distance to CYP19 
(cM) 
Hiltunen et al. 2001 15q21.1 D15S659 P = 0.036 2 
Scott et al. 2003 15q22 D15S1507 LOD = 2.8 15 
Scott et al. 2003 15q22 D15S153 LOD = 3.1 17 
Blacker et al. 2003 15q26 D15S642 MLS = 1.3 77 
LOD, Logarithm of odds score. 
MLS, Multi-point lod score. 
 
2.7. Seladin-1 
2.7.1. Seladin-1 or DHCR24 
Selective Alzheimer’s disease indicator-1 (seladin-1) or 3β-hydroxysterol ∆24-
reductase (DHCR24) gene is located on chromosome 1p31.3-p33, and contains nine 
exons. It encodes a 60.1 kDa protein that belongs to the flavin adenine dinucleotide 
(FAD)-binding oxidoreductase family (Waterham et al. 2001). Seladin-1 catalyzes the 
reduction of the delta-24 double bond in a series of enzymatic reactions converting 
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lanosterol to the final product of isoprenoid/cholesterol biosynthesis pathway, 
cholesterol, in endoplasmic reticulum (figure 5).  
 
 
 
 
 
 
 
 
 
Figure 5. Cholesterol and steroid biosynthesis pathways, and localization of seladin-1 enzyme in the 
cholesterol synthesis pathway (Waterham and Wanders 2000).  
The sequence of the various enzyme reactions required for converting lanosterol to 
cholesterol may vary, but two major routes, having 7-dehydrocholesterol or desmosterol 
as the ultimate precursors of cholesterol, have been proposed (Bae and Paik 1997, 
Waterham and Wanders 2000). Seladin-1 is highly expressed in brain and adrenal gland 
with moderate expression in liver, lung, spleen, prostate and spinal cord. Defects in 
seladin-1 can lead to desmosterolosis, a rare autosomal recessive disorder characterized 
by multiple congenital anomalies and elevated levels of the cholesterol precursor 
desmosterol in plasma, tissue, and cultured cells (Waterham et al. 2001). Human 
seladin-1 gene was identified by its sequence similarity with the plant enzyme 
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DIMINUTO/DWARF catalyzing partially similar reaction in steroid/sterol biosynthesis 
of plants (Waterham et al. 2001).    
2.7.2. Seladin-1 in neuronal degeneration and apoptosis 
In normal brain, seladin-1 is strongly expressed in neuronal cells, but in brains affected 
by Alzheimer’s disease, seladin-1 expression in the temporal lobe is substantially 
reduced compared to the frontal cortex. In normal control subjects, neuronal expression 
of seladin-1 is identical in frontal and temporal cortices (Greeve et al. 2000), indicating 
that there is a loss of seladin-1 expression in brain regions vulnerable in AD, due to the 
reduced amounts of the transcript in the remaining neurons and not simply reflecting the 
neuronal cell loss (Greeve et al. 2000). This is in line with previous findings indicating 
lower activities of antioxidant enzymes in temporal cortices of AD brains compared to 
the temporal cortices of normal brain (Marcus et al. 1998). 
Differential activity of antioxidant enzymes in nerve cell populations may be one cause 
for the selective resistance of specific cells against degeneration caused by toxic factors 
such as Aβ. In cell culture, overexpression of seladin-1 protects cells from apoptosis 
induced by Aβ, and a high expression of seladin-1 is associated with resistance against 
Aβ-induced toxicity (Greeve et al. 2000). Seladin-1 protects cells from oxidative stress 
by reducing caspase-3 activity, which activates the caspase cascade responsible for 
apoptosis execution, and this might prevent or delay the neurodegeneration in AD 
(Greeve et al. 2000). Seladin-1 probably is a component of the cellular machinery 
protecting cells from oxidative stress, but when the stress becomes overwhelming, 
seladin-1 is cleaved and probably inactivated. Under these conditions, the non-covalent 
FAD-binding domain of seladin-1 locating within the caspase cleavage motifs is 
cleaved in cells undergoing apoptosis (Greeve et al. 2000). Transcriptional activation of 
antioxidant enzymes has been attributed to resistance of cultured cells against Aβ 
toxicity (Behl et al. 1994, Sagara et al. 1996, Sagara et al. 1998), and seladin-1 may 
function in concert with these enzymes in protecting cells from oxidative stress and Aβ.    
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2.8. HSPG2 or perlecan 
2.8.1. Proteoglycans, HSPGs and perlecan 
Proteoglycans are a heterogenous superfamily of proteoglycan macromolecules, 
composed of linear sulphated polysaccharides, glucosaminoglycans (GAGs), covalently 
attached to a core protein. Proteoglycans are associated with all kinds of amyloid 
deposits in the human body. These complex macromolecules have also been implicated 
in several features of AD, including the genesis of senile plaques, cerebrovascular 
amyloid and neurofibrillary tangles. Heparan sulphate proteoglycans are a subgroup of 
proteoglycans with heparan sulphate as the polysaccharide moiety, and they are the 
most important group of proteoglycans associated with amyloid deposits (van Horssen 
et al. 2003).  
Heparan sulphate proteoglycan 2 (HSPG2) or perlecan is the largest extracellular 
matrix-associated HSPG, and an integral component of basement membranes. Perlecan 
has a 400 – 470 kDa core protein composed of five domains with homology to other 
extracellular matrix and adhesive proteins (figure 6). Domain I is unique for the 
proteoglycan since it shares no significant homology with any other protein, and 
contains three Ser-Gly-Asp sequences that act as attachment sites for heparan sulphate 
GAGs. Domains II to V contain repeats similar to low density lipoprotein receptor, 
laminin, epidermal growth factor and neural cell adhesion molecule (Noonan et al. 
1991).  The perlecan core protein is post-translationally modified by attachment of N- 
and O-linked oligosaccharides forming the heparan sulphate chains. Perlecan has a 
strong tendency to aggregate in dimers or stellate structures, and it interacts with other 
basement membrane components such as laminin, prolargin and collagen type IV. It is 
responsible for the fixed negative electrostatic charge, and is involved in the charge-
selective ultrafiltration properties, as well as serving as an attachment substrate for cells. 
Defects in HSPG2 cause two types of skeletal disorders: the mild Schwartz-Jampel 
syndrome, which is characterized by permanent myotonia and skeletal dysplasia (Nicole 
et al. 2000), and the lethal neonatal dyssegmental dysplasia Silverman-Handmaker type 
(Arikawa-Hirasawa et al. 2001). Both diseases prove that perlecan plays an important 
part in neuromuscular function and cartilage formation.  
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Figure 6. Schematic representation of perlecan protein (van Horssen et al. 2003).  
2.8.2. HSPGs and tau 
Heparan sulphate and hyperphosphorylated tau coexist in nerve cells of AD brain at the 
earliest known stages of neurofibrillary pathology, and moreover heparan sulphate and 
heparin stimulate the formation of paired helical-like filaments (Goedert et al. 1996). 
Furthermore, the presence of sulphated GAGs increases the ability of several kinases to 
phosphorylate tau (Mawal-Dewan et al. 1992, Brandt et al. 1994, Yang et al. 1994), 
causing tau to dissociate from microtubules (Goedert et al. 1996). When highly 
sulphated GAGs bind to the microtubule-binding repeat region of tau, their binding to 
microtubules is prevented. Thus GAGs might cause a conformational change in tau 
promoting microtubule disassembly and polymerization of tau molecules, which 
ultimately leads to the formation of insoluble paired helical filaments (Perry et al. 1991, 
Hasegawa et al. 1997, Hernandez et al. 2002). The magnitude of the GAG effects on tau 
hyperphosphorylation is proportional to their degree of sulphation; the more sulphated 
GAGs like heparin are more potent at evoking tau hyperphosphorylation (Hasegawa et 
al. 1997). 
2.8.3. HSPGs and β-amyloid 
The localization of HSPGs in neuritic plaques has been widely debated. Studies from a 
decade ago reported the presence of perlecan in neuritic plaques of AD and Down’s 
syndrome (Snow et al. 1988, Snow et al. 1990). When infused together to rat brain, 
Perlecan 4391 aa 
 
            SEA (Sperm protein, Enterokinase, Agrin) 
            LDL-receptor class A module 
            IgG-like repeats similar to N-CAM 
            LE, Laminin-1 EGF-like repeats 
            LamB, short arm of laminin-1 
            LamG, Laminin G-domain 
            EG, EGF-like repeats 
            Heparan sulphate  
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perlecan and β-amyloid were found to form amyloid deposits similar to the amyloid 
plaques present in human AD brain (Snow et al. 1994). There are multiple interactions 
between perlecan and Aβ; perlecan binds Aβ proteins, accelerates Aβ fibril formation 
and maintains Aβ fibril stability (Castillo et al. 1997). The sulphate moieties on the 
GAGs are critical for enhancement of Aβ fibril formation, and other sulphated GAGs 
may also participate in the fibril formation (Castillo et al. 1999). To date, perlecan and 
agrin are currently the only proteoglycans known to directly interact with Aβ (Castillo 
et al. 1997, Cotman et al. 2000). 
The question remains whether deposition of HSPGs precedes the accumulation of 
Aβ and hyperphosphorylated tau or vice versa. In Down’s syndrome brains, HSPGs are 
found in diffuse primitive senile plaques, and the accumulation of proteoglycans seems 
to be an early event in the formation of senile plaques (Snow et al. 1990). Diffuse senile 
plaques primarily composed of non-fibrillar Aβ are thought to gradually transform into 
classic senile plaques with a central core of fibrillar Aβ (Selkoe 1991, Dickson 1997). 
Perlecan and agrin promote the conversion of non-fibrillar Aβ into fibrillar Aβ, and 
contribute to increased neurotoxic properties of Aβ (Snow et al. 1994, Castillo et al. 
1997, Verbeek et al. 1997). 
HSPGs may also protect Aβ against proteolytic degradation (Gupta-Bansal et al. 1995) 
by functioning as chaperones that form a protective shield against extracellular 
proteases. Simultaneously Aβ1-40 possibly inhibits the activity of heparanases, and 
thereby prevents the proteolytic breakdown of the proteoglycans (Bame et al. 1997), 
which may indirectly contribute to the stability and persistence of plaques. Heparin also 
increases the secretion of APP, and moreover the secretion of sAPPβ, indicating that 
highly sulphated GAGs may promote the amyloidogenic pathways of APP metabolism 
(Leveugle et al. 1997). In contradiction, recent data revealed that heparan sulphate could 
inhibit β-secretase (BACE1) activity and it decreased the amount of sAPPβ and 
Aβ (Scholefield et al. 2003), probably by binding to BACE1 and thus blocking its 
access for APP. 
The role of HSPG2 on β−amyloid pathology has been debated, since novel studies using 
monoclonal antibodies have questioned the earlier reports concerning the localization of 
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perlecan in senile plaques and neurofibrillary tangles. Recently, heparan sulphate GAG 
and agrin, syndecans and glypican have been detected in senile plaques and 
neurofibrillary tangles, whereas perlecan has not been detected (van Horssen et al. 
2003).   
2.8.4. HSPGs and ApoE 
HSPGs have been linked to ApoE through several biochemical findings. ApoE binds 
heparin with high affinity (Cardin et al. 1986), stimulates HSPG2 mRNA and protein 
production as well as heparan sulphate production in vivo (Paka et al. 1999a, Paka et al. 
1999b). The ApoE4 isoform also stimulates sulphation of GAG chains more efficiently 
than the ApoE3 isoform (Bonay and Avila 2001), which in turn is associated to more 
efficient tau hyperphosphorylation and Aβ fibril formation (Hasegawa et al. 1997, 
Castillo et al. 1999). In the presence of lipoproteins, apoE4 secreting cells have reduced 
neurite outgrowth, branching and extension compared to apoE3-secreting cells (Nathan 
et al. 1994, Bellosta et al. 1995), and the inhibitory effect of apoE4 on neurite outgrowth 
is associated with microtubule depolymerization (Nathan et al. 1995).  
ApoE exhibits neurotoxicity in an isoform-specific manner (Marques et al. 1996, Jordan 
et al. 1998), and the neurotoxic properties appear to be mediated by an HSPG/LDL 
receptor related pathway (Tolar et al. 1997, Mahley and Ji 1999). ApoE-containing 
lipoproteins interact with HSPG before internalization through the HSPG/LDL receptor 
related pathway to neurons and other cells (Ji et al. 1993), but HSPG is also able to bind 
and internalize VLDL independent of this endocytic activity (Wilsie and Orlando 2003). 
HSPG appears also to function alone as a receptor and displays unique handling 
properties for specific isoforms of apoE, with apoE3 containing lipoproteins 
accumulating in cells more rapidly than apoE4 lipoproteins (Mahley and Ji 1999).  
2.8.5. Glucosaminoglycan therapies 
HSPGs have been linked to several characteristics of AD, including senile plaques 
composing of fibrillar Aβ, tau protein of NFTs and APOE. Altogether, these findings 
point to a noteworthy effect of the sulphation of heparan sulphate moieties of the HSPG 
glycoprotein rather than through the core protein itself. In that sense, these mechanisms 
and factors involved in regulating heparan sulphate synthesis might themselves become 
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important. Domain I of HSPG2 contains three Ser-Gly-Asp sequences that can accept 
heparan or chondroitin sulphate side chains. The acidic residues, aspartic and glutamic 
acid, primarily determine the targeting of GAGs in serine residues of HSPG2. The SEA 
module in the C-terminal region of domain I and the presence of multiple acceptors in 
close proximity can enhance heparan sulphate synthesis at targeted sites (Dolan et al. 
1997). This may indicate that sequences in non-GAG-binding regions of the core 
protein can influence the utilization of GAG attachment sites.  
Proteoglycans bind Aβ leading to fibril and finally to plaque formation (Castillo et al. 
1997, Dickson 1997, Verbeek et al. 1997). A binding site in 13-16 region of Aβ peptide 
represents a unique target site for inhibitors of Aβ fibril formation (Fraser et al. 1992), 
and drugs inhibiting the binding of Aβ peptide to proteoglycans might have therapeutic 
value via increased turnover of Aβ peptide by natural proteases (van Horssen et al. 
2003). In in vivo and in vitro studies, small polysulphated compounds protect against 
Aβ induced effects (Kisilevsky and Szarek 2002). In mouse model, these low-
molecular-weight sulphate compounds reduce the progression of inflammation-
associated amyloid (Kisilevsky et al. 1995), and low-molecular-weight heparin 
derivatives interfere with the binding of heparin to APP and inhibit the β-secretase 
cleavage of APP (Leveugle et al. 1998). In addition to potential use in AD, therapeutic 
inhibitors of amyloid formation may be valuable also in other amyloid disorders.    
Another basis for glycosaminoglycan therapies comes from inhibition of apoE-related 
neurotoxicity. ApoE exhibits neurotoxicity in an isoform-specific manner (Marques et 
al. 1996, Jordan et al. 1998), and all toxic apoE species include both receptor-binding 
and heparin-binding regions (Weisgraber et al. 1983, Libeu et al. 2001). The neurotoxic 
properties appear to be mediated by an HSPG/LDL receptor related pathway (Tolar et 
al. 1997, Mahley and Ji 1999), and therefore compounds disrupting the binding of apoE 
to HSPG could be effective in inhibiting the neurotoxic properties of apoE. Sulphated 
oligosaccharides, as well as heparin and heparan sulphate, prevent the neurotoxicity 
caused by apoE peptides. The synthetic compounds have better protective effects but 
also cause clumping and detachment of cells (Bazin et al. 2002).    
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Whether targeted against Aβ or apoE neurotoxicity or tau phosphorylation and 
microtubule disassembly, small polysulphated compounds mimicking sulphated GAGs 
can be considered as a promising therapeutic strategy against AD and disorders with the 
related pathological hallmarks. The CSF concentrations of HSPGs or GAGs might also 
serve as indicators of their accumulation in AD brains. No link has been found between 
AD severity and CSF concentrations of HSPGs (Briani et al. 2002), but studies in larger 
patient populations detecting specific proteoglycan subtypes might offer a basis for 
converting biochemical analysis of CSF into a useful diagnostic tool (van Horssen et al. 
2003). 
2.8.6. HSPG2 and AD 
A genome-wide linkage disequlibrium (LD) mapping study (Hiltunen et al. 1999, 
Hiltunen et al. 2001) revealed chromosomal loci 1p36.12 to be associated with late-
onset AD (table 5). The HSPG2 gene resides in this chromosomal region, and thus it 
might be regarded as a susceptibility candidate for AD. The HSPG2 gene consists of 97 
exons, and it is expressed in several tissues including the brain. Although HSPG2 has 
been considered as a promising candidate in the AD pathogenesis, there is only one 
report available concerning the possible genetic involvement of HSPG2 in AD 
(Rosenmann et al. 2004). 
Table 5. Evidence for linkage/association in chromosome 1p36 near HSPG2 locus observed in full 
genome screens.  
Study Chromosomal 
location 
Marker Linkage/association Distance to 
HSPG2 (Mb) 
Hiltunen et al. 2001 1p36 D1S552 P = 0.0006 2.9 
Hiltunen et al. 2001 1p36 D1S2644 P = 0.072 3.1 
Blacker et al. 2003 1p36 D1S1597 MLS = 1.1 8.4 
Kehoe et al. 1999 1p36 D1S1675 MLS = 2.67 92.5 
 1p36 D1S548  14.5 
Myers et al. 2002 1p36 D1S1675 TLS = 1.72 92.5 
MLS, Multi-point LOD score. 
TLS, Two-point LOD score. 
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3. AIMS OF THE STUDY 
The aim of the study was to find new candidate genes that might affect the risk of 
developing AD. Genetic studies so far have identified three genes that cause 
autosomally inherited familial Alzheimer’s disease, and often the gene mutations behind 
these familial forms can predispose the affected individuals to AD at a rather early age. 
However, the majority of people suffering from AD are affected at a later age, around 
80 years of age. Quite a few genes have been identified that predispose an individual to 
the late-onset form of AD, with APOE being the most widely acknowledged.  
Our study population consisted mainly of late-onset AD patients and their age-matched 
controls. The purpose was to use the homogenous eastern Finnish population to identify 
new candidate genes for AD from chromosomal regions that were found to be in linkage 
disequilibrium with AD in a whole genome scan of this population, and also to study 
their possible mechanisms of action using gene expression methods. The specific aims 
were: 
1) To study the role of CYP19 gene polymorphisms in a sporadic AD population 
(I). 
2) To determine the effect of CYP19 gene expression in estrogen deprivation and 
estrogen replacement (II) 
3) To compare the expression of seladin-1 gene in AD and normal, aged brains and 
to determine the possible changes in seladin-1 expression during aging in 
wildtype and AD disease model mice, and in neuronal cells during apoptosis 
(III). 
4) To study the role of HSPG2 gene polymorphism in a sporadic AD population 
(IV). 
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4. SUBJECTS, MATERIALS AND METHODS 
4.1. Subjects 
The study subjects were from eastern Finland, and they were examined in the Kuopio 
University Hospital. The studies were approved by the ethical committee of Kuopio 
University Hospital. Study III was part of a project focusing on risk genes of AD that 
had been approved by the local ethical committee, and the use of tissue was sanctioned 
by the Office of Legal Health Care Affairs. The clinically diagnosed patients fulfilled 
the criteria of probable AD according to NINCDS-ADRDA (McKhann et al. 1984). The 
patients with onset age < 65 years of age did not carry common mutations in APP, 
PSEN-1 or PSEN-2 genes. A total of 218 subjects (25% of study I population) was 
involved in both studies I and IV. 
Study I 
The case group consisted of 394 AD patients. The mean age at the onset of symptoms 
was 72 ± 7 years (range 43 to 90 years). The sample was predominantly women (70%), 
and 45% had a positive family history of AD, i.e. at least two first-degree relatives in 
two generations were affected, but there was inconclusive evidence of autosomal 
dominant transmission (Lehtovirta et al. 1996). The control group consisted of 469 
subjects who were not demented according to interview and neuropsychological testing. 
Their mean age was 70 ± 5 years (range 60 to 87 years) at the time of neurologic 
examination. The majority were women (60%). APOE ε2/3/4 allelic frequencies 
differed as expected for the case (n = 394; 0.02/0.52/0.46) and control (n = 469; 
0.04/0.80/0.16) groups (p < 0.001) in the study population. The estimates of relative 
risks of disease, ORs, were calculated using binary logistic regression with 95% 
confidence intervals (CI). APOE ε4 was five-fold more common for cases (OR = 4.74; 
95% CI 3.79 to 5.94) and associated with a three-year earlier onset age (71 vs 74 years; 
p < 0.001).  
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Study III 
Postmortem samples (Kuopio Brain Bank) obtained since 1991 were evaluated. The AD 
group consisted of eight patients, the DLB group of six patients and a control group of 
six subjects. The clinical diagnosis of AD assessed by neurologists was based on the 
NINCDS-ADRDA criteria (McKhann et al. 1984) and the diagnosis of other dementias 
on the DSM-III-R criteria (American Psychiatric Association 1987). The 
neuropathological investigation was carried out according to standard procedures, and 
the diagnosis of AD was based on the CERAD criteria (Mirra et al. 1991), and the 
diagnosis of DLB on consensus guidelines produced by an international workshop 
(McKeith et al. 1996). Temporal and occipital cortices were selected for transcription 
analysis, as they represented the most severely affected and the most spared cortical 
region (Arnold et al. 1991, Braak and Braak 1991). 
Study IV 
The study group consisted of 213 patients with AD and 269 age matched controls from 
clinical or population-based follow-up studies. The mean onset age of clinical AD 
patients was 71 ± 7 years (range 48 to 82 years; 59% women). In addition to clinical 
diagnosis, 85 (40%) cases were autopsied and the diagnosis of AD was confirmed 
according to the neuropathologic criteria of CERAD (Mirra et al. 1991). The mean 
onset age of these neuropathologic patients was 73 ± 10 years (range 45 to 92 years; 
82% women). The controls were nondemented; 80 (30%) controls were autopsied and 
neuropathologically confirmed not to demonstrate AD pathology and 189 (70%) were 
neurologically examined nondemented subjects. The mean age at the time of 
neurological examination of 189 age matched controls was 71 ± 7 years (range 42 to 87 
years; 63% women) and the mean age at the time of death of the 80 control subjects was 
78 ± 6 years (range 70 to 98 years; 45% women). As expected, the distribution of APOE 
ε2/ε3/ε4 alleles in the AD and control groups was 0.02/0.58/0.40 and 0.04/0.79/0.17, 
respectively, and the APOE ε4 allele was strongly associated with AD, giving an OR of 
3.3 (95% CI 2.5 - 4.5; p < 0.001). 
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4.2. Animals and cell lines 
The housing conditions of National Animal Center, Kuopio, Finland were controlled 
(temperature +21°C, light from 7:00 AM to 7:00 PM; humidity 50-60%), and food and 
fresh water were freely available. All efforts were made to minimize the animal 
suffering, and to reduce the number of animals used and to utilize alternatives to in vivo 
techniques. The experiments were conducted according to the Council of Europe 
(Directive 86/609) and Finnish guidelines, and approved by the State Provincial Office 
of Eastern Finland. For RT-PCR and Aβ analysis, the brain was removed and 
hippocampi, cortex and olfactory bulb were dissected. Brain samples were frozen in 
liquid nitrogen and then stored at -70°C until RNA extraction and Aβ analysis. 
Study II 
Animals and experimental design. This study consisted of two experiments, referred to 
as Experiment I and Experiment II. In both experiments, the mice were ovariectomized 
(OVX) at the age of three months. The OVX mice received estrogen treatment for the 
last five weeks of their lifetime and the control groups of OVX mice were given a 
placebo treatment. In Experiment I, estrogen was administered via intraperitoneal 
injection of 20 µg of 17β-estradiol diluted in sesame oil (i.p., one hour prior to 
behavioural testing). In Experiment II, the estrogen was administered via 
subcutaneously implanted estrogen pellets (IRA, USA) containing 0.18 mg of 17β-
estradiol that delivers a continuous supply of estrogen for 90 days. According to the 
manufacturer, the pellet yields serum estradiol levels of 50-75 pg/ml, which is similar as 
serum estradiol levels of 35-75 pg/ml reported in mice during proestrus (Nelson et al. 
1992, Grasso and Reichert 1996). The OVX mice received sesame oil via subcutaneous 
injection. The mice were killed at the age of 4.5 months in Experiment I and at the age 
of 11 months in Experiment II. 
The total number of animals used in the study was 49. Serum estrogen levels were not 
measured. Instead, the weight of the uterus was used to confirm the success of 
ovariectomy and of 17β-estradiol treatment. Uterine tissue is very responsive to 
estrogen, and therefore uterine weight was used as an index of circulating estrogen 
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levels to assess the efficacy of ovariectomy and hormone delivery (Kelner et al. 1982, 
Branham et al. 1993).  
Study III 
Transgenic animals. Female non-transgenic and double transgenic mice coexpressing 
human PSEN-1 harboring a familial AD-linked A246E mutation and chimeric 
mouse/human APP695 harboring a human Aβ domain with mutations (K595N, M596L) 
linked to Swedish familial AD pedigrees (APPswe) (Borchelt et al. 1997) were used in 
the study. The total number of animals used was 44. 
Expression gene constructs. Expression plasmid pHD-WT containing a human wild-
type presenilin-1 (PSEN-1) 1.4 kb cDNA under herpes simplex virus thymide kinase 
promoter and plasmid pHD-∆E9 encompassing an inframe deletion of codons 290-319 
produced from pHD-WT using the site-directed PCR-mutagenesis procedure (ExSiteTM 
PCR-Based Site-Directed Mutagenesis Kit, Stratagene, La Jolla, CA, USA) were used. 
Both pHD-WT and pHD-∆E9 constructs were sequence analysed using ABI Prism 310 
genetic analyzer (Applied Biosystems, Foster City, CA, USA). Expression plasmid 
pEGFP-F (Clontech, Palo Alto, CA, USA) encoding for a farnesylated membrane-
bound enhanced green fluorescent protein was used to control transfection conditions 
and efficiency.  
Cell cultures and treatment of cultures. Mouse N2a neuroblastoma cells (American 
Type Culture Collection, CCL 131) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 2 mM L-glutamine. In apoptosis experiments, exponentially 
growing N2a cells (plated 18-24 h before transfections, 60-70% confluence) were 
transfected on 60 mm plates either with wild-type PSEN-1 (pHD-WT), ∆E9 PSEN-1 
mutant (pHD-∆E9), or control vector (pHD) using FuGENE 6 reagent (Roche 
Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer’s 
instructions. In a total volume of 4 ml per plate, 2.5 µg of each plasmid DNA and 7.5 µl 
FuGENE 6 reagent were used. DNA/reagent complex was removed after 3 or 12 h, and 
apoptosis was induced with okadaic acid (OKA; Calbiochem-Novabiochem, San Diego, 
CA, USA) culturing the cells in medium with or without 25 nM OKA for 36 or 45 h. 
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Okadaic acid is an inducer of apoptosis (Nuydens et al. 1998, Suuronen et al. 2000), and 
it is known to induce in vivo an Alzheimer’s type hyperphosphorylation of tau (Harris et 
al. 1993, Gong et al. 2000, Bennecib et al. 2001). OKA treated and untreated cells were 
collected 48 h after initiation of transfections and subjected to the analyses of caspase-3 
activity (Suuronen et al. 2000) and seladin-1 semi-quantitative reverse transcriptase 
(RT) PCR analyses. Expression of wild-type and mutant PSEN-1 at 48 h after 
transfection initiation was controlled using RT-PCR with human specific PSEN-1 PCR 
primers and Western blotting with N-terminal antibody for PSEN-1. 
4.3. Gene analyses 
4.3.1. DNA and RNA extractions 
Standard procedures were used to extract genomic DNA from leucocytes (Vandenplas 
et al. 1984) and from paraffin-embedded tissue of postmortem cases (Isola et al. 1994). 
Total RNA was extracted from human and mouse cortical and hippocampal tissue 
samples using Trizol reagent and from cultured cells using Trizol LS (Gibco BRL, 
Grand Island, NY, USA). The total RNA was DNase treated using RNase-Free DNase 
Set (QIAGEN GmbH, Hilden, Germany). The quality of RNA was determined by 
electrophoresis through ethidium bromide stained agarose gel. All PCR amplifications 
and RT reactions were carried out using a PTC-200 Peltier Thermal Cycler (MJ 
Research, Waltham, MA, USA). 
4.3.2. Sequence analyses 
The PCR products and polymorphism sites of studies I, III and IV were ascertained with 
cycle-sequencing using the automated ABI PRISM 310 laser fluorescence sequencer. 
PCR primers are listed in table 6. PCR products were purified using QIAquick™ PCR 
Purification Kit (QIAGEN Qiagen) and cycle-sequenced with the genetic analyzer and 
ABI PRISM Sequencing Analyzis Software (Applied Biosystems). The sequencing was 
conducted with the dReady Dye Terminator Cycle Sequencing Kit with AmpliTaq DNA 
polymerase FS (Applied Biosystems). 
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4.3.3. Determination of CYP19 polymorphisms 
Nine intragenic SNPs were investigated, each having a minor allele frequency > 0.1, 
and covering the promoter/5’-untranslated (5’-UTR), coding/intronic and 3’-
untranslated (3’-UTR) regions at 6-23 kb intervals (figure 7).  
SNP1                        SNP2                  SNP3          SNP4   SNP5   SNP6           SNP7   SNP8    SNP9
23 kb                      20 kb                     21 kb 9 kb     6 kb          15 kb        9 kb    8 kb 
Untranslated first exon
Coding exon
I.f                             ATG 
Figure 7. Genomic structure of the CYP19 gene and the location of nine intragenic SNPs used in the 
study. I.f; brain specific promoter/first untranslated exon (Iivonen et al. 2004). 
Amplification of SNPs was performed in two multiplex PCRs with 25 ng of genomic 
DNA and 4 pmol of primers (Primers F and R in table 6) with AmpliTaq Gold DNA 
polymerase (Applied Biosystems). PCR amplification was followed by Shrimp alkaline 
phosphatase (SAP, Amersham Pharmacia Biotech) and ExoI (New England Biolabs 
Inc.) enzymatic treatment with 4 µl of both multiplex PCR products. SAP/ExoI treated 
PCR products (4 µl of both) were subjected to SNaPshot multiplex PCR in a 10 µl 
reaction volume containing 1.25 µl SNaPshot Multiplex Ready Reaction Mix (Applied 
Biosystems) and 1-3 pmol of each SNaPshot primer (Primers SS in table 6). The 
SNaPshot multiplex reaction was followed by enzymatic SAP treatment. The samples 
were analyzed using ABI 3100 Genetic Analyzer (Applied Biosystems) and the allele 
determination was carried out with the Genotyper 3.7 program (Applied Biosystems).  
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Table 6. SNPs and PCR primers used in association studies I and IV.  
Study SNP dbSNPa Location in 
gene 
Variation Primersb PCR product
(bp) 
Annealing 
temperature 
(°C) 
I CYP19/1 1004984 5'UTR C/T F:     CTGGTTTGAGGACTCTAAGGATGG 
R:     ATCACTGATGGACCCTGTGAGC 
SS1: CCCATGACTGCCTACTGTT 
243 61 
 CYP19/2 730154 5'UTR A/G F:     TAGCCCTTCAGACAGAAGATGC 
R:     CTCATTGCTAATGTGAGCTTGC 
SS2: CAGCAAAACTTCATGGAGC 
245 61 
 CYP19/3 1902586 5'UTR C/T F:     CACAACTGAACCTGATGCAGTGAC 
R:     GAAAACTTGAATGCAGGGTGGAG 
SS3: CCTGATGCAGTGACAATCA 
190 61 
 CYP19/4 1008805 5'UTR T/C F:     TGTCCTTACCGAATCACTACCCT 
R:     CCACTTTACAGATGTGGCTTGG 
SS4: ACTACCCTTCACCTTCCTG 
197 61 
 CYP19/5 767199 5'UTR C/T F:     CAGTGTGTAGCTCCGTGAAGGTT 
R:     GGCAGTCCCAAGCTCTAGTGTCT 
SS5: AGGTGACATGAATGTGGAG 
212 61 
 CYP19/6 727479 Intron 2 T/G F:     GCTCAAGATGGGGTGGAGTAAAG 
R:     CCACTATCACCACATTCCCAAGAA 
SS6: TCCCTTTCACTTTGTTTCC 
229 61 
 CYP19/7 1065778 Intron 3 A/G F:     TGATTCAACTGGAGAAGGATGTCC 
R:     CTTGAGGACCTGAAAAGACAGGAA 
SS7: TGCATTTGCTAAGAGAGCT 
195 57 
 CYP19/8 1143704 Intron 6 A/T F:     TGCTATCGTGGTTAAAATCCAAGG 
R:     TTACCTGAGAGGCCAAGAAAAACA 
SS8: GGGAAAAAAACCAATCCAA 
202 57 
 CYP19/9 10046 3'UTR C/T F:     CTTGCACCCAGATGAGACTAAAA 
R:     GGAGGTATGCCTATAAAATGCC 
SS9: GAGAAGGCTGGTCAGTACC 
210 57 
II HSPG2 3767140 Intron 5 C/A F:     CATGTCCCATGCCCCACGTGTGCT 
R:     ATTGTAGCTGTGGCAGGCAAACTC 
241 55 
a The NCBI SNP Cluster ID (rs-number). 
b F: Forward primer, R: Reverse primer, SS: SNaPshot primer
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4.3.4. Determination of HSPG2 polymorphism 
To detect HSPG2 intron 5 polymorphism (C/A), PCR and digestion of PCR products 
were carried out as previously described (Hansen et al. 1997) (primers in table 6). The 
PCR product of 241 bp was digested with the BamHI restriction enzyme (New England 
Biolabs Inc.) and the fragments were analyzed on 2% agarose gel.  
4.3.5. Determination of APOE alleles 
APOE alleles were analyzed using PCR and HhaI (New England Biolabs Inc.) 
digestions of the PCR products with PCR primers and conditions as previously 
described (Tsukamoto et al. 1993). The heterozygote sample APOE ε2/ε4 sample was 
used as a control in each run. 
4.3.6. Expression analyses 
Study II 
The reverse transcription was performed using TaqMan® Reverse Transcription 
Reagents Kit (Applied Biosystems) to generate cDNA in a 25 µl reaction volume from 
0.5 µg of total RNA. Relative quantifications of mouse CYP19, ERα and ERβ were 
calculated using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the 
endogenous control. Real-time quantification of CYP19, ERα and ERβ gene 
expressions were carried out using ABI PRISM® 7000 Sequence Detection System with 
FAM dye-labeled fluorescent assays (Assays-On-Demand™ Gene Expression Products, 
Applied Biosystems), and the endogenous control gene, GAPDH with VIC dye-labeled 
TaqMan® Rodent GAPDH Control Reagents kit (Applied Biosystems). Amplifications 
were performed in singleplex reactions with 10 to 40 ng cDNA in a 15 µl reaction 
volume with PCR cycling from 40 to 44 cycles. The amplification of GAPDH was 
performed with 50 nM GAPDH primers and 200 nM GAPDH probe.  
The relative quantification was calculated using the relative standard curve method. The 
R2 for the standard curves varied from 0.944 to 0.993. For each experimental sample, 
the amounts of target (CYP19, ERα/β) and housekeeping gene were determined from 
the appropriate relative standard curves. The target amount was then divided by the 
endogenous control (GAPDH) amount to obtain a normalized target value. A calibrator 
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was included in each assay run, and each normalized target value was divided by the 
calibrator to generate the relative expression levels. The means calculated from three 
parallel PCR reactions were used in statistical analysis. Control reactions were 
performed to verify that no amplification occurs without cDNA. 
Study III 
Semi-quantitative RT-PCR analysis. Human seladin-1 primers extended from coding 
exons 5 to 9 of human seladin-1 genomic sequence (table 7), and human nicastrin 
primers covered exons 6 to 13 of human nicastrin genomic sequence. Amplification of 
human cytoplasmic β-actin was used as a positive control and internal standard in every 
sample, and β-actin pseudogene amplification was prevented using β-actin primers 
described earlier (Raff et al. 1997). Creation of a genomic DNA amplification product 
of the same size as the reverse-transcribed target was prevented with DNase treatment 
of the RNA samples and by using PCR-primers covering several exons. In semi-
quantitative RT-PCR of mouse seladin-1, hypoxanthine phosphoribosyltransferase 
(HPRT) was used as a positive control and internal standard in every sample. Mouse 
seladin-1 primers were designed to extend from coding exons 7 to 9 of C57BL/6J strain 
mouse seladin-1 mRNA sequence.  
RT-PCR amplifications were carried out using QIAGEN OneStep RT-PCR Kit 
(QIAGEN). RT-PCR parameters were selected for both seladin-1 and control gene 
amplification reactions to be in a linear range in a multiplex reaction, when product 
intensities were logarithmically related to cycle numbers and equally strongly amplified. 
Control reactions were performed to verify that no genomic DNA amplification 
occurred without reverse transcriptase enzyme using Taq-Polymerase (Promega, 
Madison, WI, USA). AlphaImager™ 1200 and AlphaEase™ Software (Alpha Innotech 
Corporation, Catalina, CA, USA) were used in spot density calculations to quantificate 
RT-PCR products. All RT-PCR reactions were duplicated and the means calculated 
from individual reactions were used in statistical analysis.  
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Northern blot analysis. A total of 15-20 µg total RNA from human and mouse brain 
tissues and cells was separated on 1% formaldehyde-agarose gel and blotted on Magna 
Graph nylon membrane (Osmonics Inc., Minnetonka, MN, USA). Northern blots were 
hybridised with [32P]-labeled mouse seladin-1 probe. The seladin-1 probe was amplified 
using MSelF1 and MSelR primers with QIAGEN OneStep RT-PCR Kit from mouse 
total RNA. The probe sequence was 90% identical with the corresponding human 
sequence. 
Table 7. Expression primers used in study III. 
Primer Chr. Primer sequence 5’-3’ PCR 
product 
(bp) 
Number 
of PCR 
cycles 
Annealing 
temperature 
(°C) 
Human seladin 
SelF 
SelR 
Human β-actin 
AktβF 
AktβR  
Human nicastrin 
HNicF 
HNicR 
Mouse seladin 
MSelF1 
MSelF2 
MSelR 
Mouse HPRT 
HPRTF 
HPRTR 
1p33-p31.1 
 
 
7p15-p12 
 
 
1q22-q23 
 
 
4 
 
 
 
X 
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30 
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4.4. Neuropathology 
Studies III and IV 
NFTs and NPs were quantified on Bielschowsky silver stained sections under light 
microscopy with a 100x magnification as described earlier (Mölsä et al. 1987, Alafuzoff 
et al. 1999). The visualization and the quantification of Aβ aggregates, paired helical 
filament tau (PHF-τ) and α-synuclein were carried out as described earlier (Alafuzoff et 
al. 1999, Parkkinen et al. 2001). For immunohistochemical techniques, antibodies to 
human βA4, at a dilution of 1:100 (M872, DAKO, Glostrup, Denmark), to human PHF-
τ at a dilution of 1:100 (BR-03, Innogenetics, Ghent, Belgium), to rat-synuclein-1 
(ZYMED, San Francisco, CA, USA) at a dilution of 1:1000, and the streptavidin–
alkaline phosphatase system (Histomark Kit, 71–00-39) were used. The reaction 
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product, the streptavidin-biotin complex, was visualized with Vector-Red (Vector Labs, 
SK-5100). 
4.5. Protein and enzyme activity analyses 
4.5.1. Aβ40 and Aβ42 analysis 
For Aβ40 and Aβ42 assay the hippocampi were homogenised in guanidine buffer in 
proportion to their weight. The levels of Aβ40 and Aβ42 were quantified using the 
Signal Select™ Beta Amyloid ELISA Kits (Biosource International Inc., Camarillo, 
CA, USA) according to the manufacturer's protocol. The Aβ40 and Aβ42 levels were 
standardised to brain tissue weight and expressed as ng (Aβ)/g (brain tissue). 
4.5.2. Western blot analysis  
Western blot analysis of PSEN-1 was carried out with a standard procedure. Transfected 
N2a cells were lysed with RIPA lysis buffer and 40 µg of total protein per lane was 
subjected to 12% SDS-PAGE gel. After electroblotting, the nitrocellulose filters were 
blocked and probed with PSEN-1 N-terminal specific rabbit serum antibody R222 
(1:1600; a gift from Dr. P. D. Mehta, Department for Basic Research in Developmental 
Disabilities, Department of Immunology, Staten Island, NY). After washings and 
secondary antibody probing with anti-rabbit HRP conjugate (1:4000; Amersham 
Pharmacia Biotech, Uppsala, Sweden), enhanced chemiluminescence detection was 
performed. 
4.6. Statistical analyses 
The level of significance was defined as p < 0.05. Hardy-Weinberg distributions of 
genotypes were assessed by using the GenePop option 1 form 
(http://wbiomed.curtin.edu.au/). Equality of variances in one-way anova was analyzed 
using Levene’s test. 
 
 
78 
 
Study I 
Disease association. The case and control frequencies of alleles and genotypes at each 
locus were compared using two-tailed Pearson´s χ2 test and Fischer’s exact tests. 
Differences in onset ages between APOE ε4+ and ε4- cases were studied using a log-
rank statistic. The relative risk of AD was estimated from logistic odds ratios (OR) and 
95% confidence intervals (CI) adjusting for age and sex in multivariate analysis.  
LD within the CYP19 gene. Pair-wise linkage disequilibrium (LD) of SNPs was 
determined by estimating standardized D’ values for all subjects (1726 total 
chromosomes) using the 2LD program (http://www.iop.kcl.ac.uk/IoP/Departments/ 
PsychMed/GEpiBSt/ software.shtml). 
Haplotype analyses. Maximum likelihood estimates of haplotype frequencies were 
obtained using the Expectation-Maximization algorithm (Arlequin 2.0 software) after 
ruling out deviations from Hardy-Weinberg equilibrium. Haplotype frequency 
comparisons between AD and control groups with absolute chromosome numbers were 
carried out using RxC program employing the Metropolis algorithm to obtain unbiased 
estimates of exact p values with standard errors (SE) (http://bioweb.usu.edu/mpmbio/). 
Haplotype blocks were identified by pair-wise EM haplotype estimation analysis and 
then applying the four gamete test to identify obligate recombination between loci 
(Wang et al. 2002). 
Latent class analysis. The latent class analysis was performed to identify risk 
haplotypes and to verify that risk was not strongly related to age, sex or APOE 
genotype. Information on genotypes for the nine SNPs was jointly used to identify two 
groups differing in genotypic frequencies (Grade of Membership Software, Center for 
Demographic Studies, Duke University, Durham, NC (1987)) (Manton et al. 1994). 
Age, sex, APOE and disease status frequencies were calculated for each latent SNP 
group. One χ2 test was used to compare disease status for subjects who matched the 
latent SNP groups, i.e. multiple comparisons were avoided. 
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Study II 
All gene expression data are expressed as percentages of expression in OVX group. All 
statistical analyses for RT-PCR and uterine weights were performed using SPSS 11.5 
software applying T-test and Spearman’s correlation analysis. Univariate general linear 
model was applied in covariance analysis of gene expression comparisons using the 
housekeeping gene GAPDH as covariate. Values of p < 0.05 were considered to be 
significant. 
Study III 
All statistical analyses were performed using SPSS 9.0 software applying independent 
samples two-tailed t-test, nonparametric Mann-Whitney test and bivariate correlation 
analysis.  
Study IV 
Statistical analyses for comparing allele and genotype frequencies were carried out 
using two-sided Pearson´s χ2 and Fischer’s exact tests with SPSS 10.0 software. Odds 
ratios (OR), as the estimates of relative risk of disease, were calculated using binary 
logistic regression with 95% confidence intervals (CI). An interaction model in logistic 
regression analysis was used to study the interaction between HSPG2 A and APOE ε4 
alleles. The RxC program employing the Metropolis algorithm was used for analysis of 
contingency tables to obtain unbiased estimates of exact p-values with standard errors 
(SE) (http://bioweb.usu.edu/mpmbio/). For APOE4 stratified data, the Bonferroni 
correction was applied by multiplying the P values with the number of stratifications. 
PHF-tau expression and Aβ load were analysed using one-sided, nonparametric Mann-
Whitney test based on the hypothesis that the A allele of HSPG2 impairs the pathology 
in brain. 
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5. RESULTS 
5.1. CYP19 polymorphisms (Study I) 
Allelic and genotypic frequencies for adjacent SNPs 5 to 7 were significantly associated 
with AD (table 8). Flanking SNPs 4 and 8 demonstrated smaller and non-significant 
associations with AD. Hardy-Weinberg equilibrium tests were separately performed 
among AD and control groups for each locus and no deviations from equilibrium were 
observed.  
Table 8. Allele and genotype distributions of the CYP19 SNPs 1 to 9 (Iivonen et al. 2004). 
SNP Allele Allele frequency 
Control         AD  
(N = 938)       (N =788)   
 
pa 
Genotype Genotype frequency 
Control        AD 
(N = 469)     (N = 394) 
 
pa 
SNP 1 
 
C 
T 
0.77 
0.23 
0.77 
0.23 
0.92 CC 
CT 
TT 
0.58 
0.37 
0.05 
0.59 
0.35 
0.06 
0.56 
 
SNP 2 G 
A 
0.16 
0.84 
0.15 
0.85 
0.64 GG 
GA 
AA 
0.03 
0.25 
0.72 
0.02 
0.26 
0.72 
0.72 
SNP 3 C 
T 
0.91 
0.09 
0.91 
0.09 
0.97 CC 
CT 
TT 
0.83 
0.16 
0.01 
0.83 
0.16 
0.01 
1.00 
SNP 4 C 
T 
0.46 
0.54 
0.41 
0.59 
0.05 CC 
CT 
TT 
0.22 
0.47 
0.31 
0.17 
0.49 
0.34 
0.11 
SNP 5 C 
T 
0.55 
0.45 
0.50 
0.50 
0.05 CC 
CT 
TT 
0.32 
0.46 
0.22 
0.25 
0.51 
0.24 
0.04 
SNP 6 G 
T 
0.35 
0.65 
0.30 
0.70 
0.009 GG 
GT 
TT 
0.12 
0.46 
0.42 
0.09 
0.41 
0.50 
0.04 
SNP 7 G 
A 
0.45 
0.55 
0.51 
0.49 
0.03 GG 
GA 
AA 
0.22 
0.46 
0.32 
0.25 
0.51 
0.24 
0.04 
SNP 8 T 
A 
0.46 
0.54 
0.50 
0.50 
0.06 TT 
TA 
AA 
0.23 
0.46 
0.31 
0.25 
0.51 
0.24 
0.07 
SNP 9 C 
T 
0.51 
0.49 
0.47 
0.53 
0.10 CC 
CT 
TT 
0.27 
0.47 
0.26 
0.22 
0.55 
0.28 
0.13 
a P-values were calculated using two-tailed Pearson´s χ2 test (alleles) and Fischer’s exact tests 
(genotypes). 
 
Logistic regression models constructed to estimate the relative risk of AD related to the 
risk genotype(s) found at the locus compared to other genotype(s) revealed that age and 
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sex did not affect relative risks. No significant p-values were observed with the early-
onset (onset age < 65 years) AD patient group. Stratification according to gender and 
APOE status did not reveal any major differences between subgroups. The risk 
associated with adjacent SNPs 4 to 9 suggested that they might represent a high-risk 
unit, or haplotype. The possibility of a high-risk haplotype was supported by the strong 
pairwise LD between SNP loci (all subjects; 1726 chromosomes). Using a threshold D’ 
value of 0.30, 75% of SNP pairs demonstrated LD, and LD diminished with physical 
distance between SNP pairs (Pearson's correlation value = - 0.613; p = 0.01).  
Six haplotype blocks were initially identified for the study subjects with an average 
block size of 22 kb (figure 8). When allowing for a low frequency of recombination (< 
3%) to occur between two loci, only two haplotype blocks defined by SNPs 2 to 4 and 5 
to 9 (> 40 kb in size) were identified. 
SNP1 SNP 2 SNP 3 SNP 4 SNP 5 SNP 6 SNP 7 SNP 8 SNP 9
SNP 1 0 1 1 1 1 1 1 1 1
SNP 2 0.03 0 0 0 1 1 1 1 1
SNP 3 0.18 1.00 0 0 1 0 1 1 1
SNP 4 0.12 0.99 0.99 0 1 1 1 1 1
SNP 5 0.07 0.82 0.95 0.67 0 1 1 1 1
SNP 6 0.45 0.01 0.99 0.62 0.93 0 0 1 1
SNP 7 0.20 0.78 0.95 0.64 0.95 0.99 0 1 1
SNP 8 0.19 0.79 0.95 0.62 0.93 0.99 0.98 0 1
SNP 9 0.13 0.37 0.14 0.64 0.91 0.99 0.96 0.97 0
Figure 8. Identification of haplotype blocks within the CYP19 gene region. Solid and dotted lines 
represent the configurations when no recombination and < 3% proportion of recombination are allowed 
between two loci, respectively. Four gamete test results performed between pair-wise loci: 0 and 1 
indicate the absence and presence, respectively, of all four gametes estimated according to EM-based 
haplotype analysis. D’ values for SNP pairs are indicated for the comparison of the haplotype block 
arrangement and the LD across the CYP19 region (Iivonen et al. 2004). 
Haplotypes displaying frequencies > 0.05 were included in haplotype association 
analyses that revealed the overall distribution of haplotypes derived from SNPs 1 to 9 to 
differ between AD and control groups (p = 0.039 ± 0.008)(table 9). Haplotype A1 
including risk alleles for SNPs 5 to 7 was over-represented among AD patients. 
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Conversely, haplotype A2 (the complement of A1 for SNPs 4 to 9) was less common in 
the AD cases. Haplotype frequencies for the SNP block defined by SNPs 5 to 9 differed 
for AD and control groups (p = 0.039 ± 0.010), whereas the frequencies for the SNP 
block defined by SNPs 2 to 4 did not differ (p = 0.109 ± 0.012).    
Table 9. Estimated haplotype frequencies for SNP 1 to 9 (Iivonen et al. 2004). 
Haplotypea Control 
(N = 938) 
AD 
(N = 788) 
pb 
CACTTTGTT (A1) 0.300 0.350 0.021 ± 0.001 
CACCCGAAC (A2) 0.270 0.214 0.011 ± 0.004 
CACCCTAAC (A3) 0.055 0.064 0.555 ± 0.011 
TACCTTGTT (A4) 0.054 0.060 0.675 ± 0.009 
Others 0.321 0.312 0.532 ± 0.024 
Overall   0.039 ± 0.008 
a EM estimated haplotypes displaying frequencies ≥ 0.05 are indicated in table. Nucleotides indicated in 
bold were significantly over-represented in the AD group in single-locus analyses.     
bP-values calculated using RxC program (± S.E). 
SNP latent class analysis distinguished the haplotypes into two genetic groups I and II 
based on genotype information for the CYP19 SNPs and APOE. The groups were 
similar for SNPs 1 to 3 and differed for SNPs 4 to 9. APOE genotypic frequencies did 
not appreciably differ for the two genetic groups, nor did age or sex distributions. The 
genetic groups differed in AD risk: Group II had a 49% AD frequency, compared to 
38% for group I or group II had a 60% increased risk of AD (OR = 1.6, 95% CI 1.1 to 
2.2). 
5.2. CYP19 expression in ovariectomized mice (Study II) 
5.2.1. Uterus weight 
The efficacies of ovariectomy and estrogen treatments were monitored by measuring the 
fresh weight of uterus immediately after killing the mice. All OVX mice had uterine 
weights below 30 mg, and in both experiments, estrogen treated mice had significantly 
increased uterine weights (p < 0.001) compared to OVX mice. When comparing only 
ERT mice, uterine weights of mice receiving tonic ERT in Experiment II were higher 
compared to those receiving phasic ERT in Experiment I (p = 0.003). Therefore, gene 
expressions in both studies were reanalyzed after normalizing uterine weights of the 
ERT groups by excluding three to four mice with the lowest uterine weights in both 
experiment groups, to test whether the differences in brain aromatase and ERs gene 
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expressions between phasic and tonic ERT groups persisted after the groups have been 
equalized with respect to the peripheral effect of estrogen. After the normalization, the 
statistical differences remained unchanged (figure 9). 
5.2.2. Normalization with GAPDH  
The target gene expressions were compared without GAPDH normalization (normalized 
with total RNA amount), with GAPDH normalization and with GAPDH normalization 
using covariance analysis. Covariance analysis, using housekeeping gene expression as 
a covariant to extract its effect from target gene expression, gave similar results in group 
comparisons with the GAPDH normalized data, whereas gene expression comparisons 
without normalization with GAPDH led to differing results from the aforementioned 
methods. 
The approximate Ct values values with 40 ng of total RNA converted to cDNA for 
CYP19, ERα and ERβ were 35, 30 and 33, respectively, indicating that genes were 
expressed in the order  ERα > ERβ > CYP19 in mouse hippocampus. 
5.2.3. CYP19, ERα and ERβ expression in ovariectomized mice 
In Experiment I, the phasic ERT decreased significantly CYP19 expression by 51 % (P 
= 0.003) and ERα expression by 47 % (P < 0.001), whereas the small change in 
ERβ expression was not significant (P > 0.05) (figure 9A). In Experiment II, the tonic 
ERT increased significantly CYP19 expression by 69 % (P < 0.001), ERα expression by 
86 % (P < 0.001) and ERβ expression by 51 % (P < 0.001) (figure 9B). In Experiment I, 
the phasic ERT decreased the ERα/ERβ ratio by 42 % (P = 0.04) compared to the OVX 
group, but the ratio remained almost the same in OVX mice with or without tonic ERT 
(Experiment II) (P > 0.05). The gene expressions considered to reflect brain estrogen 
status correlated strongly with each other. Furthermore, uterine weights, that reflect the 
peripheral response to estrogen, correlated weakly but significantly with the gene 
expressions in the brain. 
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Figure 9. CYP19, ERα and ERβ gene expressions and uterine weights in ovariectomized (OVX), and 
estrogen treated mice. The bars represent mean gene expressions as percentages of expression in OVX 
group, or uterine weights (mg), and error bars represent SEMs. A and B describe the values for all the 
subjects, whereas C and D describe the values for phasic and tonic ERT, respectively, after normalizing 
the data according to the uterine weights of ERT mice. The gene expressions and uterine weights, 
injection (AC) and pellet groups (BD) were compared to OVX group, and the P values calculated with T-
test are displayed (*** < 0.001). 
5.3. Seladin-1 transcription and neuronal degeneration (Study III) 
5.3.1. Seladin-1 transcription in human brain tissue 
The relative transcription of seladin-1 was downregulated by 27% in demented subjects 
(n = 14), and moreover, by 33% in definite AD subjects (n = 9) compared to 
nondemented individuals (n = 6). In half of the AD patients, the relative transcription of 
seladin-1 was lower in temporal cortex compared to occipital cortex, whereas in 
nondemented subjects, the transcription of seladin-1 was higher or equal in temporal 
cortex compared to the occipital cortex. Subjects with DLB lacking AD pathology (n = 
3) had equal relative transcription of seladin-1 to that found in nondemented subjects. 
Transcription analysis of another AD-associated gene, nicastrin, did not reveal any 
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differences in the relative transcription between demented and nondemented subjects 
(table 10). 
The severity of AD pathology correlated with downregulation of seladin-1 transcription; 
the relative transcription of seladin-1 was significantly lower in subjects with NFTs or 
NPs compared to subjects with no AD hallmark lesions (table 11), which was also seen 
as a negative correlation between these pathological hallmarks and seladin-1 
transcription (NFT: R = - 0.499; P = 0.025, and NP: R = - 0.521; P = 0.019). Subjects 
with numerous fibrils both in cortical and hippocampal areas had also lower relative 
seladin-1 transcription than subjects with positive PHF-τ labeling in hippocampal 
regions. This difference was also seen as a negative correlation between PHF-τ labeling 
score and seladin-1 transcription (R = - 0.516; P = 0.020), whereas no correlation 
between seladin-1 transcription and Aβ or α-synuclein pathology was found. 
Table 10. Statistical analysis of seladin-1 and nicastrin transcription data in human temporal versus 
occipital cortex. 
Status N Relative transcription 
(Mean ± SD) 
Minimum Maximum P-valuea 
Seladin-1      
Nondemented 6 1.47 ± 0.48 1.00 2.29  
Demented 14 1.06 ± 0.37 0.53 1.77 0.069 
DefADc 9 0.98 ± 0.32 0.53 1.56 0.045 
 All ADsc 13 1.01 ± 0.32 0.53 1.56 0.044 
All DLBsd 6 1.13 ± 0.45 0.67 1.77 0.200 
Pure DLBsd 3 1.49 ± 0.31 1.15 1.77 0.796 
Nicastrin       
Nondemented 6 1.11 ± 0.32 0.82 1.57  
Demented 14 1.01 ± 0.33 0.53 1.68 0.509 
DefADc 9 1.01 ± 0.36 0.53 1.68 0.556 
 All ADsc 13 1.03 ± 0.33 0.53 1.68 0.661 
All DLBsd 6 0.92 ± 0.32 0.53 1.43 0.337 
Pure DLBsd 3 1.06 ± 0.36 0.71 1.43 0.796 
a P-values calculated using nonparametric Mann-Whitney test. 
c Definite and all AD cases according to CERAD classification. 
d All demented cases having DLB pathology and pure DLB cases without AD pathology. 
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Table 11. Relative transcription of seladin-1 compared in subjects with none or mild neuropathology and     
subjects with more extended and severe stage of neuropathology. 
Stage of 
neuro- 
pathology 
 
Location of  
neuropathology 
N Total scoring of 
neuropathology 
(Mean±SEM)a 
Relative 
transcription of  
seladin-1 
(Mean±SEM) 
P-valuea 
NFT- cortex 9 - 1.50 ± 0.15  
NFT+ cortex 11 17.2 ± 2.6 0.95 ± 0.09 0.004 
NP- cortex 6 - 1.63 ± 0.19  
NP+ cortex 14 15.7 ± 2.5 1.01 ± 0.08 0.006 
PHF-τ+ hippocampus 8 1.4 ± 0.2 1.49 ± 0.16  
PHF-τ+ hippocampus &cortex 12 9.4 ± 0.8 1.00 ± 0.09 0.016 
Aβ- cortex 4 - 1.53 ± 0.27  
Aβ+ cortex 16 4.6 ± 0.7 1.11 ± 0.10 0.148 
α-synuclein- substantia nigra, gyrus 
cinguli & hippocampus 
11 - 1.20 ± 0.10  
α-synuclein+ substantia nigra, gyrus 
cinguli & hippocampus 
9 4.0 ± 0.6 1.19 ± 0.19 0.656 
a P-values calculated using nonparametric Mann-Whitney test. 
5.3.2. Seladin-1 transcription in APPswe/PSEN1 transgenic mice 
APP/PSEN-1 double transgenic mice display detectable Aβ40 and Aβ42 levels at the 
age of 4 months, and amyloid levels increase thereafter dramatically with age. Time 
points before (4 months), at early phase (11 months) and at severe phase (16-17 months) 
of amyloid accumulation were selected to study the changes in seladin-1 transcription 
during aging and in the course of amyloid deposition. Parietal cortex was chosen to 
represent more affected and olfactory bulb as less affected tissue in mice. The relative 
transcription of mouse seladin-1 fluctuated during aging. A 15% decrease in seladin-1 
transcription was seen between the ages of 4 and 11 months both in control and 
transgenic mice, but the decrease was significant only in transgenic mice (P = 0.042). 
Between the ages of 11 and 16 months the seladin-1 transcription increased by 28%, 
which was seen in both animal groups, but this was significant only in transgenic mice 
(P = 0.002). No correlation between the relative transcription of seladin-1 and 
hippocampal Aβ40 and Aβ42 levels was found. 
5.3.3. Seladin-1 transcription in apoptosis model 
Mouse N2a neuroblastoma cells transfected with human wildtype or ∆E9 PSEN-1 
constructs were used to study the possible effect of PSEN-1 transcription on 
endogenous seladin-1 transcription in apoptosis. The induction of apoptosis with 
okadaic acid was established by measuring the caspase-3 activity from cell lysates. 
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After 36 h exposure to okadaic acid, caspase-3 activity was highly elevated, and after 45 
h exposure, caspase-3 activity was already 14-fold higher when compared to untreated 
N2a cells. After 36 h exposure to okadaic acid, the caspase-3 activity was lowest in ∆E9 
PSEN-1 group, but after 45 h, the caspase-3 activity was significantly higher than after 
36 h (P = 0.016). In control (pHD) and wild-type PSEN-1 transfected groups, the 
caspase-3 activities were essentially the same after 36 and 45 h. 
The relative transcription of seladin-1 increased in time, or it was higher after 45 h than 
after 36 h of exposure in all treatment groups. Seladin-1 up-regulation was most striking 
in the wild-type PSEN-1 transfected, okadaic acid treated group, in which the seladin-1 
transcription increased by 69% from 36 h to 45 h, whereas the increase in okadaic acid 
treated ∆E9 PSEN-1 group was only 7%.     
 
Figure 10. Caspase-3 activity and seladin-1 transcription in mouse N2a cells induced to apoptosis. Bars 
show means of six individual experiments, error bars show SEM. (A) Caspase-3 activation in vector, 
wild-type and ∆E9 PSEN-1 transfected N2a cells 36 and 45 h after induction of apoptosis with 25 nM 
okadaic acid (OKA+) and in control cells (OKA-). The asterisk indicates significant difference (P < 0.05) 
between 36 h and 45 h ∆E9 PSEN-1 transfected, OKA+ cells. (B) The relative transcription seladin-1 in 
vector, wild-type and ∆E9 PSEN-1 transfected N2a cells 36 and 45 h after induction of apoptosis with 25 
nM okadaic acid and in control cells. The transcription of seladin-1 was related to the transcription of the 
HPRT gene (Iivonen et al. 2002). 
5.4. HSPG2 polymorphism (Study IV) 
Allele and genotype distributions of HSPG2 did not differ between AD and control 
populations, and HSPG2 genotypes were in Hardy-Weinberg equilibrium in both 
populations. No modulatory effect of gender was observed. However, both genotype 
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and allele frequencies differed between AD and control populations carrying the APOE 
ε4 allele (table 12). 
Table 12. HSPG2 genotype and allele distributions (Iivonen et al. 2003). 
Group  na         Genotypes 
 CC       CA       AA 
Pb     Alleles 
  C          A 
Pb 
All AD 213 0.53      0.39      0.08  0.72      0.28  
 C 269 0.57      0.37      0.06 0.465 0.76      0.24 0.266 
APOE4- AD 81 0.49      0.40      0.11  0.69      0.31  
 C 191 0.51      0.42      0.07 0.481 0.72      0.28 0.535 
APOE4+ AD 132 0.55      0.39      0.06      0.74      0.26  
 C 78 0.72      0.26      0.02 0.043 0.85      0.15 0.014 
an, number of Alzheimer’s disease patients (AD) and controls (C). 
bFisher's exact test for genotype data and Pearson's χ2 test for allele data.  
 
In ε4 carriers, the combined CA+AA genotype (OR = 2.1; 95% CI 1.2 - 3.9) and the A 
allele (OR = 1.9; 95% CI 1.1 - 3.1) frequencies were higher among the AD than in the 
control population. The results pointed out an interaction or an additive effect between 
the HSPG2 A and APOE ε4 alleles, and logistic regression revealed that HSPG2 A 
allele was not an independent risk factor for AD (OR 1.1), whereas in conjunction with 
the ε4 allele, it doubled the risk for AD (from OR 3.1 to OR 6.6) when compared to 
APOE ε4 alone (table 13). The interaction between APOE and HSPG2 was studied 
using an interaction model in the logistic regression analysis. No significant interaction 
was observed between the two genes (OR = 2.0; 95% CI 0.9 – 4.4; p = 0.086) indicating 
that this represents alternatively an additive effect of HSPG2 on APOE ε4 carriers. 
Table 13.  Odds ratios of the risk for AD when taking the subjects with neither APOE ε4 nor HSPG2 A 
alleles as the reference (Iivonen et al. 2003). 
APOE 
24/34/44a 
HSPG2 
CA/AAa  
AD  
n (%) 
Control  
n (%)  
OR 
 (95% CI)b  
Pb 
- - 40 (19) 97 (36) Reference  
- + 41 (19) 94 (35) 1.1 (0.6-1.8) 0.832 
+ - 72 (34) 56 (21) 3.1 (1.9-5.2) <0.001 
+ + 60 (28) 22   (8) 6.6 (3.6-12.2) <0.001 
aThe minus sign indicates subjects lacking these genotypes; plus indicates subjects with these genotypes. 
bBinary logistic regression analysis. 
 
In the neuropathologically defined group, the OR for AD in HSPG2 A allele carriers 
with ε4 allele was 8.3 (95% CI 2.8 - 24.3; p < 0.001) and in non-carriers with ε4 allele 
5.3 (95% CI 1.8-15.3; p = 0.003) when compared to the reference group without these 
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alleles. In the clinical group, the equivalent ORs were 5.3 (95% CI 2.5 - 11.5; p < 0.001) 
and 2.8 (95% CI 1.5 - 5.0; p = 0.001).  
The neuropathological markers of AD, Aβ and PHF-tau, were studied in relation to the 
HSPG2 C/A polymorphism. AD cases with ε4 and HSPG2 A alleles had a 17% higher 
PHF-tau expression compared to ε4 carriers without the HSPG2 A allele (p = 0.046; 
95% CI 0.041 - 0.052), whereas in the control group, no significant difference was 
observed (p = 0.130; 95% CI 0.121 - 0.139). In Aβ load, there was no significant 
difference between the stratified groups in AD population, although a 12% increase in 
the Aβ load among the ε4 carriers with HSPG2 A allele compared to those without A 
allele was detected. Furthermore, no differences were found in the control population. 
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6. DISCUSSION 
In the present series of studies, a cluster of CYP19 SNPs associated with AD, forming a 
haplotype with a 60% increase in the risk of AD. In an animal model of female 
postmenopause and ERT, the CYP19 expression responded differently to tonic and 
phasic hormone replacement, with tonic ERT increasing the expression of CYP19 and 
also having beneficial memory effects. Downregulation in seladin-1 transcription in AD 
was associated with hyperphosphorylation of tau protein which indicated that seladin-1 
may also be downregulated in other dementias involving hyperphosphorylation of tau 
protein. Also, the HSPG2 gene encoding for perlecan protein of basement membranes 
was associated with a subpopulation of late-onset AD cases, indicating that HSPG2 may 
be involved together with APOE ε4 allele in the pathophysiology of AD. The 
methodological aspects and results of these studies are discussed in this chapter. 
 
 
 
 
 
 
Figure 11. Factors implicated in Alzheimer’s disease and the association of the genes of this study to 
them.      
6.1. Methodological considerations 
6.1.1. Study populations 
Although Finland, and especially the Kuopio region are considered as isolated 
populations, they do not differ from larger admixed populations, possibly due to the 
larger founding population than previously believed (Wright et al. 1999, Jorde et al. 
2000). In the North Savo population, which is part of the late settlement region in 
Finland, the regions of LD have diminished when compared to isolated subpopulations 
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like Kuusamo (Varilo et al. 2003). For polygenic disorders, the frequencies of 
underlying disease-causing mutations may be high enough so that even a small founder 
population will contain multiple mutations on multiple haplotype backgrounds, 
obscuring associations between a disease phenotype and a linked marker (Kruglyak 
1999). This addresses the need for careful characterization of population to ascertain 
that they are true isolates. Nevertheless, a rapidly growing population with decaying LD 
provides an efficient tool for finer-scale gene localization. 
The drawback of using isolated populations in association-based mapping is the 
relatively low number of chromosome copies not closely related to one another, when 
the sample size may become an issue (Bonne-Tamir et al. 1997). Decreased 
heterozygosity of polymorphic markers may also decrease the power of association 
studies in isolated populations, as does their relatively short histories that allow a 
limited resolution of the location of the disease gene. The Finnish population may be 
one of the few populations, in which relative isolation has persisted long enough to 
allow fine-scale mapping of Mendelian disorders affected by recent mutations, but it 
remains to be seen whether this population will be useful for more complex disorders 
(Jorde et al. 2000). Isolated populations of constant size might be more useful for 
mapping genes underlying complex diseases than populations recently expanded in size, 
of which Finland is a good example. In constant-sized populations, genetic drift can 
produce new disequilibrium more quickly than recombinations, but in rapidly 
expanding populations, genetic drift is inhibited and the accumulation of new risk 
alleles continues (Hartl and Clark 1997). The constant-sized Ainu and Saami 
populations show increased LD, and they may be more appropriate for mapping genes 
for complex traits caused by older mutations, whereas recently expanded populations 
are convenient for mapping single disease genes affected by recent mutations (Laan and 
Paabo 1997, Lonjou et al. 1999).  
6.1.2. Candidate gene association studies 
Selecting a right candidate gene is the first challenge in performing a candidate gene 
association study. For example, for neuronal disorders, all genes expressed in brains 
may be considered as potential candidate genes. When a gene and polymorphism(s) 
have been chosen, and the study has been performed, there is a chance that in case of 
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negative association, the real association in nearby SNP may have been missed due to 
negative linkage disequilibrium. To avoid this possibility, and because of the high 
variability in the extent of linkage disequilibrium across the genome, a whole-genome 
linkage disequilibrium map should be available if one wishes to carry out a successful 
association study.   
A systematic genome-wide linkage disequilibrium mapping using tens of thousands of 
candidate-SNPs in a case-control association study, could avoid this problem, but the 
extremely high number of SNPs needed and the resulting high costs hamper the 
performance of such studies. DNA pooling has been introduced as a solution, but the  
accurate interpretation of SNP allele frequencies might prove to be problematic (Baron 
2001).    
Furthermore, statistical issues puzzle researchers performing association studies. When 
setting the p-value criteria critically to avoid false-positive associations, there may never 
be enough power to detect modest gene effects with confidence (Terwilliger and Weiss 
1998). The search for susceptibility genes of complex diseases may require complex 
solutions, and joint linkage and association studies (Baron 2001) might be efficient to 
reliably and cost-efficiently map susceptibility genes with both large and intermediate 
effects on the risk of developing disease in reasonable-sized sample populations. 
6.1.3. Real-time RT-PCR 
The real-time quantitative PCR offers a new dimension in sensitivity when compared to 
older reverse transcription methods, but this sensitivity also places higher demands on 
understanding and meeting the methodological demands. The quantification of real-time 
PCR can be performed using a standard curve or comparative Ct method that requires 
approximately equal efficiencies for target and housekeeping gene PCR amplifications 
(Giulietti et al. 2001). In study II, the requirement for equal PCR amplification 
efficiencies was not met, and the relative standard curve method was applied. The 
benefits of the standard curve method are the standard dilutions that are included in each 
PCR run providing an extra control and correction for PCR efficiency, making the 
interassay comparison more reliable (Giulietti et al. 2001). 
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A reliable quantitative RT-PCR method requires correction for variations in individual 
reverse transcription and PCR efficiencies. Using real-time PCR, these problems are 
minor, since the quantification is based on Ct values, which are determined very early in 
the exponential phase of the reactions as opposed to end-point analysis. The 
normalization to a housekeeping gene is currently the most acceptable method to correct 
for minor variations in RNA input amount or reverse transcription efficiency (Giulietti 
et al. 2001). When analyzing the results, it is important to consider the possible 
differences in housekeeping gene expressions in order to avoid making false positive or 
negative conclusions.  
It has been suggested that the unadjusted values of target genes without normalization 
with a housekeeping gene, might actually be the best estimates of the real change in 
gene expression (Bond et al. 2002). Even without  housekeeping gene expression 
normalization, gene expressions are normalized by the amount of total RNA used in 
reverse transcription and PCR amplification, since the same amount of RNA converted 
to cDNA is used in real-time PCR for all samples. According to our results, this may 
not be sufficient, indicating that the reverse transcription or PCR amplification 
efficiencies vary between the samples. Bond et al. (2002) has recently proposed the use 
of covariance analysis in gene expression studies. Analyzing target gene expressions 
using housekeeping gene expression as a covariate is recommended, if the housekeeping 
gene expression is altered by the treatments (Bond et al. 2002). According to present 
study, the univariate general linear model using GAPDH expression as a covariate gave 
similar results with the GAPDH normalized results. Although the requirement for equal 
variances was not met, covariance analysis gave identical results with nonparametric 
Kruskall-Wallis test that does not require either normal distribution or equal variances. 
Thus, the normalization by the amount of total RNA does not seem to be adequate, but 
both normalizing by calculating target gene to housekeeping gene expression relation, 
or using housekeeping gene expression as a covariate might assist in drawing more 
realistic conclusions from the data in question.    
6.1.4. Statistical analyses 
Expression studies are usually conducted with rather small sample numbers because of 
the expense involved in expression analysis and the complicated statistics needed 
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following the analysis. As a consequence of small sample numbers, the observations 
seldom are normally distributed, and the use of nonparametric tests is recommended. 
Nonparametric tests rank the individual values and analyses are based on the 
distribution of ranks resulting in loss of original information regarding the individual 
observations and group means. Nonparametric tests are less powerful than the 
parametric tests, meaning that p-values tend to be higher, rendering it harder to detect 
real differences as being statistically significant.  
In study III, nonparametric tests were used because of the small sample number and the 
abnormal distribution of the values. In this study, nonparametric tests proved powerful 
in detecting significant differences, and since the differences were substantial, they are 
also considered to be accurate. 
6.2. CYP19 
LD and haplotype blocks. CYP19 gene displayed considerable LD between SNP pairs 
up to 40 kb, but at greater distances, the standardized D’ values diminished. The 
majority of chromosomes were accounted for by two major haplotypes (high-risk and 
low-risk), and the third haplotype found had a low (5%) frequency for both case and 
control groups. To detect haplotype blocks, a four-gamete test application was used 
(Wang et al. 2002). When a small proportion of recombination (< 3%) was allowed to 
occur between two loci, two haplotype blocks defined by the SNPs 2 to 4 and 5 to 9 
within the CYP19 gene region were found. SNP 1 locating at the 5’ prime end of the 
CYP19 gene was considered to belong to an undefined block flanking the gene region. 
The distribution of proposed blocks suggested that the recombination crossover site was 
located between SNPs 4 and 5, following basically the promoter/5’-UTR and 
coding/intron/3’-UTR organization. SNP pairs between the blocks displayed also 
considerable LD, indicating that the recombination frequency at the crossover region is 
low. A second implication of the strong LD observed at the region is that EM algorithm 
estimates of SNP haplotype frequencies should be accurate (Xu et al. 2002). Several 
studies have proposed that the human genome is arranged into block-like patterns of LD 
that may be useful in defining disease susceptibility genes (Daly et al. 2001, Jeffreys et 
al. 2001, Reich et al. 2001, Wang et al. 2002), and the low haplotype diversity of 
95 
 
CYP19 gene supports this notion with its genomic region arranged into two haplotype 
blocks with low between-block recombination frequency.  
Disease associations. CYP19 was implicated as a susceptibility gene for AD in this 
candidate gene-based association study of a large clinic-based series of AD patients and 
nondemented subjects, these results being particularly supported with the existence of a 
common high-risk haplotype. This haplotype was over-represented in cases using two 
analytic approaches which both estimated ~60% excess risk for the high-risk haplotype. 
The independence of CYP19 polymorphism from APOE genotype in both single-locus 
analyses and latent SNP groups suggested that CYP19 polymorphism is probably an 
independent risk factor for AD. Moreover, the risk related to CYP19 was likely to be 
similar for men and women and operated over a wide range of age: raw and age-sex 
adjusted logistic estimates of risk were essentially the same, and the low-risk and high-
risk latent SNP groups had similar age-sex distributions. 
The functional significance of haplotype block of SNPs 5 to 9 associated to AD remains 
to be determined. The SNPs significantly associated with AD were located more to the 
intron and 3’-UTR parts of the gene than to the large 5’-UTR region. Thus, it would be 
more likely that the functional alteration responsible for disease association, and which 
probably is in LD with the SNPs 4 to 9, would be at the coding/intron or 3’ regulatory 
region of the CYP19 gene. It is also possible that some other susceptibility gene located 
at the 3’ flanking region of CYP19 gene is actually responsible for the disease-
association seen, but the nearest 3’ flanking gene is located more than 70 kb from the 
end of CYP19 gene, and though it is improbable that the observed association would be 
accounted for by this unknown gene. Two novel studies identified an association 
between CYP19 polymorphisms and aromatase activity or estradiol levels (Berstein et 
al. 2004, Dunning et al. 2004) supporting the possible relevance of CYP19 
polymorphisms on AD by their ability to modify estrogen levels. 
The single locus genotype and allele frequencies of SNPs were only moderately 
different between cases and controls, but there are two aspects that support the idea of a 
true association rather than false positive result. A series of associated SNPs across the 
intron/3’-UTR parts of the gene, which are basically also located into a single haplotype 
block support the idea of true association (Terwilliger et al. 1997). Second, two different 
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statistical approaches, that are also less sensitive to multiple testing as SNPs were 
considered jointly not individually and they also implicated CYP19 as a susceptibility 
gene for AD. In other large genome screening studies, chromosome 15 has not attracted 
much attention (Pericak-Vance et al. 1998, Kehoe et al. 1999, Pericak-Vance et al. 
2000, Myers et al. 2002) or the linkage region found has been located far (15q26, 79 
cM) from the CYP19 gene (Blacker et al. 2003) suggesting that the CYP19 possesses 
only a moderate effect in AD and thus this gene region may have been missed in 
previous linkage-based genome screenings. Recently, however, one study identified 
genetic markers 15 and 17 cM distally to CYP19 that were associated with AD (Scott et 
al. 2003) supporting the relevance of this genomic region as an AD susceptibility 
region. 
CYP19, ERα and ERβ expression in estrogen deprivation and ERT. The down-
regulation of CYP19 gene expression by phasic ERT is consistent with previous 
findings on mouse diencephalon (Yamada et al. 1993). Phasic ERT may possibly 
decrease the production of testosterone and dehydroepiandrosterone sulfate via the 
hypothalamic/pituitary axis feedback (Casson et al. 1997), and the subsequent decrease 
in the amount of aromatase substrate androgens might explain the down-regulation of 
CYP19 gene expression. In addition, steroid hormone binding globulin, which binds 
steroid hormones slowing hormone degradation and excretion, is increased during ERT, 
further decreasing the amount of free testosterone in plasma (Casson et al. 1997). These 
events together may cause the overall decline of free plasma testosterone levels in ERT 
explaining the downregulation of CYP19 gene expression. In contrast to ERT with 
injections, the tonic estrogen therapy used in this study upregulated CYP19 expression. 
The opposite response may result from the exposure to prolonged, tonically high 
hormone levels that may dampen the regulation of hypothalamic/pituitary axis feedback 
or cellular transcription machinery. 
The regulation of CYP19 gene expression is complex. In addition to being a substrate of 
the aromatase enzyme, androgens may regulate CYP19 gene expression, since CYP19 
mRNA contains androgen and estrogen responsive elements, that may stabilize the 
CYP19 mRNA and increase the CYP19 gene expression (Harada et al. 1993, Lephart 
1996, Bourguiba et al. 2003). In addition, the promoter region of human brain specific 
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CYP19 mRNA contains potential androgen and glucocorticoid binding sites (Honda et 
al. 1994). Gonadal hormones affect CYP19 expression; testosterone induces and 
estradiol inhibits the activity of this enzyme. The regulation of brain aromatase 
expression may also be affected by other gonadal hormones since the effects of 
testosterone and estradiol are more substantial in ovariectomized mice than in intact 
animals (Yamada et al. 1993). The effects are inhibited by androgen and estrogen 
receptor antagonists, but ER antagonists do not prevent the effects of testosterone on 
aromatase expression. This suggests that these hormones use different signaling 
pathways to regulate aromatase expression (Bourguiba et al. 2003). According to 
another theory, exogenous androgen can be aromatized to estrogen which would act 
through ER, while the remaining androgen acts through the AR. Together these two 
receptors may modulate the CYP19 gene expression (Balthazart et al. 2003). This view 
is supported by findings of co-localization of aromatase and androgen receptor on the 
one hand (Balthazart et al. 1998), and aromatase and ERα on the other hand (Balthazart 
et al. 1991). 
The expression profile of ERα in response to estrogen manipulations was very similar to 
CYP19. One previous study reported ERα up-regulation in rat cerebral cortex after 
OVX and down-regulation to normal level after ERT (Mohamed and Abdel-Rahman 
2000). In the same study, the expression of ERα was down-regulated in rat cerebellum 
after OVX and up-regulated after ERT, similarly to our study. The discrepancies of ERα 
expressions in response to OVX and ERT may be attributed to different brain areas 
studied, since ERs are probably expressed cell and tissue-specifically (Carley et al. 
2003, Matthews and Gustafsson 2003). ERs show also tissue-specific autoregulation by 
estrogen (Lee and Gorski 1998), and moreover, according to this study, the delivery 
route and dose kinetics may affect the regulation of ER expression. 
ERβ expression in mouse brain has been less studied than Erα expression. A previous 
study has reported down-regulation of ERβ in the rat brain after estrogen treatment 
(Shima et al. 2003). According to our results, hippocampal ERβ expression is not 
changed in mice after phasic ERT, but it is up-regulated after tonic ERT. It has been 
suggested that the main function of the ERβ isoform may be to modulate or inhibit the 
effects of ERα (Hall and McDonnell 1999, Weihua et al. 2000, Matthews and 
98 
 
Gustafsson 2003). Thus it would be reasonable for ERβ expression to remain constant 
during hormonal changes, while ERα expression would fluctuate more extensively. The 
relative expression level of the two ER isoforms has been proposed to be a key 
determinant of the cellular responses to estrogen agonists and antagonists (Hall and 
McDonnell 1999), and in our study the expression of ERα was approximately eight-fold 
compared to ERβ expression in mouse hippocampus. Although the ERβ gene 
expression seemed unchanged by phasic ERT, ERβ protein may still respond to 
estrogen at posttranscriptional level. 
In contrast to phasic injected estrogen, tonic estrogen delivery from an implanted pellet 
up-regulated all three genes in ovariectomized female mice. Nevertheless, the effect on 
uterine weight was comparable between 20 µg of injected estrogen and the estrogen 
pellet. A similar uterine response to the pellet that releases 2 µg per day and a daily 
injection of a 10-fold estrogen dose is rather surprising at first glance. However, the 
hormone levels in the pellet mice are constant around the clock, whereas the hormone 
levels after injection peak once daily reaching supraphysiological concentrations. The 
regulation of mouse uterine ER expression has been shown to be dependent on hormone 
levels; physiological estrogen levels up-regulate ER mRNA, while supraphysiological 
levels evoke no increase in ER mRNA compared to OVX mice (Bergman et al. 1992). 
Our results suggest that brain ERs respond similarly, since ERα and ERβ expressions 
were up-regulated in pellet treated mice, but downregulated or unaffected in injected 
mice. 
Androgens have also many of the neuroprotective effects of estrogen (Papasozomenos 
1997, Hammond et al. 2001, Pike 2001, Papasozomenos and Shanavas 2002, Ramsden 
et al. 2003, Tan and Pu 2003, Leranth et al. 2004), and it is possible that androgens 
acting through androgen receptors are the neuroprotective hormones in the estrogen 
deprived brain. Supporting this theory, a recent report has shown that estrogen and 
androgens share a common downstream target, heat shock protein 70 that protects 
neurons from Aβ1-42 induced toxicity (Zhang et al. 2004). One interesting, new finding 
suggests that the maintenance of hippocampal spine synapses depends on hippocampal 
estrogen synthesis, but exogenous estrogen has no effect on these synapses (Kretz et al. 
2004). In addition, the concentration of estradiol in hippocampus is manifold compared 
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to plasma estradiol levels, indicating that in hippocampus, neurosteroids modulate 
interneuronal communication acting in a paracrine manner (Hojo et al. 2004). 
Endogenously synthesized neurosteroids might also be essential for the other 
neuroprotective functions of estrogen.  
In conclusion, the present findings indicate that ERT not only affects brain by directly 
delivering estrogen across the blood-brain barrier, but also indirectly regulates the 
estrogen synthesis in the brain by modulating the expression of the aromatase gene. 
Furthermore, estrogen has been reported to stimulate aromatase enzyme activity without 
affecting mRNA levels, pointing to posttranscriptional effects of estrogen on aromatase 
activity levels (Roselli et al. 1997). Whether the direct estrogen delivery to the brain or 
the modulation of aromatase activity is more important for the outcome of ERT remains 
to be explored in further studies. 
The present study also demonstrated that the pattern of estrogen delivery may 
dramatically change the ERT effect on the brain. Interestingly, tonic ERT with an 
implanted pellet that had beneficial memory effects also increased the level of CYP19 
and ERα gene expression, whereas injected estrogen with the same peripheral effect had 
the opposite influence on the brain. This finding suggests that the brain effects of 
peroral estrogen may also differ from the effect of transdermal estrogen. 
6.3. Seladin-1 
Human seladin-1 transcription is linked to neuronal degeneration. The expression study 
with a semi-quantitative RT-PCR method revealed that transcription of seladin-1 was 
significantly decreased in temporal cortices of AD cases compared to nondemented 
subjects, whereas in pure DLB cases, no differential transcription of seladin-1 could be 
seen. Interestingly, DLB cases carrying AD pathology had a lower transcription of 
seladin-1 in temporal cortex indicating that the differential transcription of seladin-1 in 
DLB/AD cases could be attributed to AD rather than DLB pathology. The decline in the 
relative transcription of seladin-1 was related to the presence of NFTs, NPs and PHF-τ 
fibrils but not to Aβ. Therefore, the decrease in transcription level of seladin-1 in AD 
could be considered as a marker of the neuronal degeneration occurring in AD seen as 
NFTs, NPs and neuropil threads. However, due to the limited number of cases in each 
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study group, no firm conclusions concerning the specificity of the seladin-1 mRNA 
downregulation to AD but not to other neurological diseases should be made on the 
ground of this study alone. 
To minimize the variation between samples attributable to differences in tissue 
conditions (e.g. pH) and handling, transcription of seladin-1, calculated as the 
proportion with respect to the transcription of the control gene (β-actin), was compared 
between two different brain areas, temporal and occipital cortex, in every individual 
case. Nicastrin, which served as reference data, was processed in a similar way. 
Nicastrin expressed both in neuronal and nonneuronal cells (Satoh and Kuroda 2001), 
was found to be remarkable constantly transcripted in nondemented and demented 
cases, in both temporal and occipital cortex. This confirms the belief that the decrease in 
seladin-1 transcription in temporal cortex of AD cases is due to factors other than cell 
loss alone, which was also shown previously by in situ hybridization (Greeve et al. 
2000). 
Mouse seladin-1 transcription fluctuates during aging. To study whether the decrease in 
seladin-1 transcription precedes the accumulation of amyloid deposits or is a 
consequence of amyloid accumulation, double transgenic APP/PSEN-1 mice were used. 
The amyloid deposits begin to develop around the age of 9 months in these mice, and 
the amyloid formation increases dramatically between 10 and 12 months of age. 
Amyloid deposits appear first in the hippocampus, subiculum, frontal and occipital 
cortices subsequently spreading to other cortical areas. Many of the Aβ deposits are 
associated with dystrophic neurites (PHF-ι negative) and reactive astrocytes (Borchelt et 
al. 1997). Different cortical regions are similarly affected by the amyloid deposits while 
the olfactory bulb is only slightly affected (T. van Groen, Department of Neuroscience 
and Neurology, University of Kuopio, personal communication).  
The results indicated that the relative transcription of mouse seladin-1 fluctuates during 
aging, but the transcription pattern of seladin-1 was similar in control and APP/PSEN-1 
transgenic mice, indicating that changes in seladin-1 transcription were attributable 
more to the general aging process than to the pathological changes occurring in 
transgenic mice. However, the changes were significant only between transgenic mice 
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groups, indicating that the APP/PSEN-1 mutations could enhance the effects of seladin-
1 transcription in aging. As in humans, the Aβ accumulation in animals did not show 
any relationship with seladin-1 transcription. A decline in seladin-1 transcription seen at 
the age of 11 months could have been potentiated by the amyloid deposition. On the 
other hand, the same phenomenon, although not significant, was seen in littermates of 
the same age that did not develop amyloid deposits. The increase in the seladin-1 
transcription at the age of 16-17 months compared to the levels at 11 months might be 
an attempt by the cells to compensate for the aging process and amyloid deposit 
formation. The absence of apoptotic cell loss in the transgenic mice could partly explain 
why age-matched transgenic and littermate mice did not differ in seladin-1 transcription 
during aging. This indicates that instead of Aβ accumulation, other factors such as tau 
pathology or cell loss might be needed to affect the seladin-1 transcription in AD brain. 
Induction of apoptosis increases seladin-1 transcription in N2a cells. Since PSEN-1 and 
seladin-1 have been linked to apoptosis (Guo et al. 1997, Greeve et al. 2000), an in vitro 
study with mouse N2a cells stimulated to undergo apoptosis was performed to examine 
the possible consequences of wild-type PSEN-1 and ∆E9 PSEN-1 mutation in relation 
to seladin-1 in apoptosis. Seladin-1 overtranscription protects cells from oxidative stress 
and apoptosis via caspase-3 activation (Greeve et al. 2000), however, in intense 
oxidative stress, seladin-1 is presumably inactivated mainly by caspase-6 which cleaves 
seladin-1 into a 40 kDa derivative. In addition to this derivative that possibly possesses 
a proapoptotic attribute, decreased transcription of seladin-1 may also be a death signal 
to cells leading to increased caspase-3 activation and subsequent cascade of apoptosis. 
PSEN-1 is highly expressed in nerve cell populations known to be targeted in AD, such 
as cells in hippocampus, amygdala and neocortex (Lee et al. 1996).The ∆E9 mutant 
PSEN-1 increases cell vulnerability to apoptosis, a  characteristic not seen in the case of 
wildtype PSEN-1 (Guo et al. 1997), and ∆E9 PSEN-1 also affects Aβ42 peptide 
production (Mehta et al. 1998).  
Caspase-3 activity, a measure of apoptosis, was significantly higher in all okadaic acid 
treated groups than in untreated groups, indicating that apoptosis had been initiated. 
Stalled entering of the ∆E9 PSEN-1 transfected N2a cells into the apoptotic phase that 
was seen as delayed increase of caspase-3 activity from 36 to 45 h time point when 
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compared to wildtype and vector transfected groups, could be related to the PSEN-1 
mutation involvement in arrested cell cycle (Janicki et al. 2000).  
The relative transcription of seladin-1 increased in all groups from the 36 to 45 h time 
point, suggesting that induction of apoptosis also increased the seladin-1 transcription. 
Interestingly, seladin-1 transcription in the ∆E9 PSEN-1 group was lower than in vector 
and wild-type PSEN-1 transfected groups after 45 h exposure to okadaic acid, and 
corresponded approximately to the transcription level of untreated control cells. Since 
seladin-1 is known to be able to inhibit caspase-3 (Greeve et al. 2000), this might 
explain why this group exhibited higher caspase-3 activity; this could be a 
compensation mechanism that increases apoptotic signals and also modulates to a 
certain extent the transcription of protective factors such as seladin-1. 
6.4. HSPG2 
Even though HSPG2 can be considered as a promising candidate in AD pathogenesis, 
no previous reports have been available concerning the possible genetic involvement of 
HSPG2 in AD, until recently, when an association study found no association between 
HSPG2 and AD, irrespective of APOE ε4 status (Rosenmann et al. 2004). In the present 
study, HSPG2 polymorphism alone did not associate with AD, but in APOE ε4 allele 
carriers, HSPG2 A allele did associate with AD. Although the association was 
introduced only after a stratification of the whole data, a technique which also increases 
the risk of false positive results, the observed effect between the HSPG2 A and APOE 
ε4 alleles is consistent with the current biological data. ApoE binds heparin with high 
affinity (Cardin et al. 1986), stimulates HSPG2 mRNA and the HSPG2 protein 
production as well as heparan sulphate production in vivo (Cardin et al. 1986, Paka et al. 
1999a, Paka et al. 1999b). The ApoE4 isoform also stimulates sulphation of GAG 
chains more efficiently than the ApoE3 isoform (Bonay and Avila 2001). These 
findings, together with the well-known linkage of APOE to AD, indicate that HSPG2 
might be associated with AD through the sulphation of heparan sulphate moieties of the 
glycoprotein rather than through the core protein itself. 
The sulphation of heparan sulphate moieties is also linked to tau protein and Aβ. 
Heparan sulphate and heparin stimulate the formation of paired helical-like filaments by 
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promoting phosphorylation of tau (Goedert et al. 1996), and this effect is  influenced by 
the amount of sulphation of GAG chains, with the more extensively sulphated heparan 
sulphates being more active (Hasegawa et al. 1997). Consistent with this, we were also 
able to show more abundant PHF-tau expression in neuropathologically confirmed AD 
patients carrying both APOE ε4 and HSPG2 A alleles when compared to ε4 carriers 
lacking the HSPG2 A allele. The sulphate moieties on the GAGs are also critical for 
enhancement of Aβ fibril formation (Castillo et al. 1999), and in addition, HSPG2 has 
been found to bind Aβ proteins, accelerate Aβ fibril formation and maintain Aβ fibril 
stability (Castillo et al. 1997). Overall, these findings highlight the noteworthy effect of 
HSPG2 sulphation on the association of HSPG2 with AD. 
In summary, this data suggests that some functional change in the HSPG2 gene, which 
is probably in linkage disequilibrium with the A allele, may cause changes in the 
expression or splicing status of the HSPG2 gene, and lead to an altered number of 
heparan sulphate attachment sites. In parallel to this process, the APOE4 isoform 
sulphates more efficiently the heparan sulphate disaccharide-repeating units in the 
glycoprotein (Bonay and Avila 2001), which in turn can stimulate tau phosphorylation 
and consequently lead to tau filament formation. The same mechanism may also 
underlie the Aβ fibril formation. Unfortunately, the multiple testing limits the power to 
find conclusive evidence of association, and the p-values should be viewed with 
caution. Elucidating the biological relevance of HSPG2 and APOE in AD would 
provide more definite proof of a true association. 
In the future, detailed genetic studies in different ethnic populations and expressional 
analyses using animal models of AD might offer more precise information regarding the 
conceivable role of CYP19 region in AD. In the case of seladin-1, SNP and haplotype 
analysis using SNPs covering the gene coding for seladin-1 and the nearby regions, 
together with correlation analysis with attributes of tau pathology might be worth more 
detailed examination. Also the possible downregulation of seladin-1 in other tauopathies 
could strengthen the linkage between seladin-1 and tau protein. A more detailed SNP 
analysis of HSPG2 gene region would be essential in order to confirm the authenticity 
of the association. Also the biological relevance of HSPG2 and APOE in AD might be 
an interesting objective of further functional analysis. In summary, the present series of 
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studies provide initial clues about the importance of several proteins in AD pathogenesis 
but additional research will be needed to confirm their relevance and their potential 
application in future AD therapies.        
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7. SUMMARY AND CONCLUSIONS 
The aim of the study was to find new candidate genes that might affect the risk of 
developing Alzheimer’s disease and to study the possible changes in their expression 
levels using gene expression methods. Genetic studies so far have identified only a few 
genes to be involved in early-onset age, familial forms of Alzheimer’s disease, whereas 
the majority of individuals suffering from Alzheimer’s disease are affected at a rather 
later age, as the disease usually begins after the age of 60 years. Only a few genes are 
identified that predispose to late-onset form of AD, with APOE being the most widely 
acknowledged.  
Our study population consisted mainly of late-onset AD patients and their age-matched 
controls. The purpose was to use the homogenous eastern Finnish population to identify 
new candidate genes for AD and also to study their possible mechanisms of action using 
gene expression methods.  
1.  In the CYP19 gene, a cluster of SNPs with an increased risk of Alzheimer's 
disease were found. These SNPs together formed a risk haplotype that was independent 
of sex, age and APOE polymorphism. 
2.  CYP19 and ER gene expressions were found to be affected by the hormonal 
status of mice. Depending on the delivery route and dosage of estrogen, the expression 
of CYP19 and ERα were modified, while ERβ expression was rather constant. Linking 
this to Alzheimer's disease, one could postulate that postmenopausal women, who have 
an increased risk of developing Alzheimer's disease compared to men or premenopausal 
women, might gain greater benefit from replacement of hormone delivered at constant 
low levels as opposed to oral administration of a single, high hormone dose every day. 
An assessment of the optimal delivery route of the hormone may also be worthy of 
consideration.   
3.  The transcription of seladin-1 was selectively downregulated in brain areas 
affected with the hallmark lesions of AD, and the decrease in seladin-1 transcription 
was linked to neuronal degeneration in AD, including PHF-τ, NFTs and NPs, whereas 
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no linkage could be found in human or transgenic animal studies between seladin-1 
transcription and Aβ accumulation. Furthermore, cell culture studies indicated that 
seladin-1 transcription increases in apoptotic cells, with apoptotic signals possibly 
modulating the transcription of seladin-1. In conclusion, the decrease in the 
transcription of seladin-1 found in AD was considered to be a marker for a specific 
neuronal degeneration including PHF-τ formation, rather than being a marker for 
apoptosis or the accumulation of Aβ protein. 
4. HSPG2 was identified to be a possible, additive risk factor for Alzheimer's 
disease in APOE ε4 allele carriers. In genetic analysis, the HSPG2 A allele in 
conjunction with the APOE ε4 allele doubled the risk compared to carrying the APOE 
ε4 allele alone. The tau pathology in HSPG2 A and APOE ε4 allele carriers was more 
prominent than in APOE ε4 allele carriers, suggesting that HSPG2 and APOE might 
interact at the cellular level impacting more on tau pathology rather than on Aβ 
pathology. 
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